Official Protocol Title:  
NCT number:  
Document Date:  A Phase II Trial to Investigate Genetic Markers of Response to
Pembrolizumab (MK-3475, SCH 900475) Combined with 
Chemotherapy as a First-line Treatment for Non-Small Cell Lung 
Cancer (KEYNOTE-782)
20 AUG 2021[STUDY_ID_REMOVED]
PRODUCT: MK 3475 SCH 900475 1
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase II Trial to Investigate Genetic Markers of Response to 
Pembrolizumab (MK -3475, SCH 900475) Combined with Chemotherapy as a First -line 
Treatment for Non -Small Cell Lung Cancer (KEYNOTE- 782)
Protocol Number: 782-02
Compound Number: MK-3475
Sponsor Name:
[CONTACT_44873] S harp & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey, [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND [ADDRESS_977261] [STUDY_ID_REMOVED]
Approval Date: [ADDRESS_977262] 2021
Copyright © 2021
[COMPANY_006] & Co., Inc., Kenilworth NJ [LOCATION_003], and its affiliates.
All Rights Reserved
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 2
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 3
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 2 20-AUG- 2021To include instruction allowing participants to be enrolled in a pembrolizumab 
extension study upon study completion , add final analysis in the statistical 
analysis plan, and update the Sponsor’s branding information.
Amendment [ADDRESS_977263]: MK 3475 SCH 900475 4
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: [782-02]
Overall Rationale for the Amendments:
To include instruction allowing participants to be enrolled in a pembrolizumab extension study upon study completion, add final 
analysis in the statistical analysis plan, and update the Sponsor’s branding information.
Summary of Changes Table:
Section # and Name [CONTACT_717032] a copyright statement To add clarification on copyrights
4.4Beginning and End of 
Study DefinitionAdded text of “ Upon study completion, 
participants are discontinued and may be 
enrolled in a pembrolizumab extension 
study, if available. ” To allow participants to be enrolled in a pembrolizumab 
extension study upon study completion for the medical 
benefit of the participants
9.1Statistical Analysis Plan 
SummaryAdded text “ Final analysis will occur after 
all participants have received 35 
administrations of pembrolizumab or 
discontinued study intervention .” To add final analysis to the summary of the statistical 
analysis plan
9.8Final Analysis Added a section for final ana lysis To align with the update in Section 9.[ADDRESS_977264]: MK 3475 SCH 900475 5
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 16
1.3 Schedule of Activities (SoA) ................................................................................ 17
2 INTRODUCTION .......................................................................................................... 30
2.1 Study Rationale ....................................................................................................30
Rationale for the Trial and Selected Patient Population .............................. 30
Tumor Mutation Burden .............................................................................. 32
Tumor Cell -Free DNA Analysis ..................................................................33
Microbiome Modulation of the Immun e System and Immunotherapy .......34
2.2 Background .......................................................................................................... 36
Pharmaceutical and Therapeutic Background ............................................. 37
Completed Clinical Studies.......................................................................... 37
Ongoing Clinical Studies ............................................................................. 40
[IP_ADDRESS] Pembrolizumab Studies .....................................................................40
[IP_ADDRESS] Ongoing Grail cfNA Biomarker Studies ............................................ 40
2.3 Benefit/Risk Asses sment...................................................................................... 41
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 41
4 STUDY DESIGN ............................................................................................................ 43
4.1 Overall Design ......................................................................................................43
4.2 Scientific Rationale for Study Design ................................................................ .44
Rationale for Endpoints ............................................................................... 44
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 44
[IP_ADDRESS].[ADDRESS_977265] 1.1 ........................................44
[IP_ADDRESS].[ADDRESS_977266] for Immune -based Therapeutics 
(iRECIST) ................................................................................ 45
[IP_ADDRESS] Biomarkers ......................................................................................... 46
[IP_ADDRESS].1 Circulating Free DNA Mutation Burden ................................ .46
[IP_ADDRESS].2 Tumor Mutation Burden .......................................................... 46
[IP_ADDRESS].3 Microbiome and Metabolomics ............................................... 46
[IP_ADDRESS] Safety Endpoints ................................................................................ 46
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 46
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................[ADDRESS_977267]: MK 3475 SCH 900475 6
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 49
[IP_ADDRESS] Future Biomedical Research .............................................................. 49
4.3 Justification for Dose ........................................................................................... 50
Pembrolizumab ............................................................................................ 50
Chemotherapy .............................................................................................. 50
4.4 Beginning and End of Study Definition ............................................................. 50
Clinical Criteria for Early Study Termination ............................................. 50
5 STUDY POPULATION ................................................................................................ 50
5.1 Inclusion Criteria ................................................................................................ .50
5.2 Exclusion Criteria ................................................................................................ 53
5.3 Lifestyle Considerations ...................................................................................... 56
Meals and Dietary Restrictions ....................................................................56
Caffeine, Alcohol, and Tobacco Restrictions .............................................. 56
Activity Restrictions .................................................................................... 56
Contraception ............................................................................................... 56
Pregnancy .....................................................................................................56
Use in Nursing Women ................................................................................ 57
5.4 Screen Failures .....................................................................................................57
5.5 Participant Replacement Strategy ......................................................................57
6 STUDY INTERVENTION ............................................................................................ 57
6.1 Study Intervention(s) Administered ...................................................................57
6.2 Preparation/Handling/Storage/Accountability ................................................. 59
Dose Preparation .......................................................................................... 59
Handling, Storage, and Accountability ........................................................ 59
6.3 Measures to Minimize Bias: Randomization and Blind ing.............................. 60
Intervention Assignment.............................................................................. 60
Stratification ................................................................................................ .60
Blinding ........................................................................................................60
6.4 Study Intervention Compliance .......................................................................... 60
6.5 Concomitant Therapy .......................................................................................... 60
Probiotics and Prebiotics.............................................................................. 62
Rescue Medications and Supportive Care ................................................... 62
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_977268]: MK 3475 SCH 900475 7
PROTOCOL/AMENDMENT NO.: [ADDRESS_977269] to Follow -up................................................................................................ .72
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 73
8.1 Administrative and General Procedures ........................................................... 74
Informed Consent ......................................................................................... 74
[IP_ADDRESS] General Informed Consent ................................................................ .74
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 74
Inclusion/Exclusion Criteria ........................................................................[ADDRESS_977270] .....................................................................75
Medical History ........................................................................................... 75
Prior and Concomitant Medications Review ............................................... 75
[IP_ADDRESS] Prior Medications ............................................................................... 75
[IP_ADDRESS] Concomitant Medications ..................................................................75
Assignment of Screening Number ............................................................... 75
Assignment of Treatment/Randomization Number .....................................76
Study Intervention Administration .............................................................. 76
[IP_ADDRESS] Timing of Dose Administration ......................................................... 76
[IP_ADDRESS].1 Timing of Dose Administration of Pembrolizumab ................ 76
[IP_ADDRESS].2 Timing of Dose Administration of Pemetrexed ....................... 76
[IP_ADDRESS].3 Timing of Dose of Carboplatin or Cisplatin ............................ 77
[IP_ADDRESS].3.1 Carboplatin .....................................................................77
[IP_ADDRESS].3.2 Cisplatin ......................................................................... 77
Discontinuation and Withdrawal ................................................................ .77
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 77
Participant Blinding/Unblinding ..................................................................78
Calibration of Equipment ............................................................................. 78
8.2 Efficacy/Immunogenicity Assessments .............................................................. 78
Tumor Imaging and Assessment of Disease ................................................ 78
[IP_ADDRESS] Initial Tumor Imaging ........................................................................79
[IP_ADDRESS] Tumor Imaging During the Study ...................................................... 79
[IP_ADDRESS] End- of-Treatment and Follow -up Tumor Imaging ............................ 80
[IP_ADDRESS] RECIST 1.1 Assessment of Disease .................................................. 80
[IP_ADDRESS] iRECIST Assessment of Disease ....................................................... [ADDRESS_977271]: MK 3475 SCH 900475 8
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Physical Examinations ................................................................................. 83
[IP_ADDRESS] Full Physical Examination ................................................................ .83
[IP_ADDRESS] Directed Physical Examination .......................................................... 83
Vital Signs ....................................................................................................83
Electrocardiograms ...................................................................................... 83
Clinical Safety Laboratory Assessments ..................................................... 84
[IP_ADDRESS] Laboratory Safety Evaluations (Hematology, C hemistry and 
Urinalysis) .......................................................................................... 84
[IP_ADDRESS] Pregnancy Test ................................................................................... 84
Eastern Cooperative Oncology Group (ECOG) Performance Scale ........... 85
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 85
Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 85
Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......88
Follow -up of AE, SAE, and Other Reportable Safety Event Information ...88
Regulatory Reporting Requirements for SAE ............................................. 88
Pregnancy and Exposure During Breastfeeding .......................................... 88
Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_977272] (ECIs) ................................................................ 89
8.5 Treatment of Overdose ........................................................................................ 89
8.6 Pharmacokinetics ................................................................................................ .90
8.7 Pharmacodynamics .............................................................................................. 90
8.8 Future Biomedical Research Sample Collection ............................................... 90
8.9 Planned Genetic Analysis Sample Collection .................................................... 90
8.10 Biomarkers ........................................................................................................... 91
Tissue Biomarkers ....................................................................................... 91
[IP_ADDRESS] PD-L1 IHC ......................................................................................... 91
[IP_ADDRESS] Exploratory Biomarkers .....................................................................91
Blood -based Biomarkers .............................................................................. 92
Stool-based Biomarkers ............................................................................... 92
8.11 Health Economics Medical Resource Utilization and Health Economics .......92
8.12 Visit Requirements ............................................................................................... 92
Screening ......................................................................................................93
Treatment Period .......................................................................................... 93
Discontinued Participants Continuing to be Monitored in the Study .......... 93
[IP_ADDRESS] Safety Follow- up Visit .......................................................................[ADDRESS_977273]: MK 3475 SCH 900475 9
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS] Follow -up Visits ................................................................................. 94
[IP_ADDRESS] Survival Follow -up............................................................................ 94
Survival Status ............................................................................................. 94
9 STATISTICAL ANALYSIS PLAN ............................................................................. 94
9.1 Statistical Analysis Plan Summary .....................................................................95
9.2 Responsibility for Analyses/In -house Blinding ................................................. 96
9.3 Hypotheses/Estimation ........................................................................................ 96
9.4 Analysis Endpoints ............................................................................................... 96
Efficacy Endpoints ....................................................................................... 96
Biomarker Endpoints ................................................................................... 96
Safety Endpoints .......................................................................................... 97
9.5 Analysis Populations ............................................................................................ 97
9.6 Statistical Methods ............................................................................................... 97
Statistical Methods for Biomarker/Efficacy Analyses ................................ .97
Statistical Methods for Safety Analyses ...................................................... 99
9.7 Interim Analyses ................................................................................................ 100
9.8 Final Analysis .....................................................................................................100
9.9 Multiplicity ......................................................................................................... 100
9.10 Sample Size and Power Calculations ............................................................... 100
9.11 Subgroup Analyses ............................................................................................. 101
9.12 Compliance (Medication Adherence) ............................................................... 101
9.13 Extent of Exposure ............................................................................................. 101
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................102
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ......[ADDRESS_977274] for Clinical Trials ........................................................... 102
Financial Disclosure ................................................................................... 104
Data Protection ........................................................................................... 104
[IP_ADDRESS] Confidentiality of Data ....................................................................105
[IP_ADDRESS] Confidentiality of Participant Records ............................................. 105
[IP_ADDRESS] Confidentiality of IRB/IEC Information .......................................... 105
Committees Structure ................................................................................. 105
[IP_ADDRESS] Steering Committee ......................................................................... [ADDRESS_977275]: MK 3475 SCH 900475 10
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Study and Site Closure ............................................................................... 108
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 109
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 110
Definition of AE ........................................................................................ 110
Definition of SAE ...................................................................................... 111
Additional Events Reported in the Same Manner as SAE ......................... 112
Recording AE and SAE ............................................................................. 112
Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................116
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ..................................118
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ...................... 119
Definitions ..................................................................................................119
Contraception Requirements ......................................................................120
Pregnancy Testing ...................................................................................... 121
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 122
10.7 Appendix 7: Country -specific Requirements .................................................. 127
10.8 Appendix 8: Description of the iRECIST Process for Assessment of 
Disease Progression ............................................................................................ 128
10.9 Appendix 9: Abbreviations ............................................................................... 132
10.10 Appendix 10: Eastern Cooperative Oncology Group (ECOG) 
Performance Scale ............................................................................................. [ADDRESS_977276]: MK 3475 SCH 900475 11
PROTOCOL/AMENDMENT NO.: [ADDRESS_977277] Radiologic Evidence of Progressive 
Disease .......................................................................................................... 82
Table 10 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events .............................................................................. 87
Table 11 Analysis Strategy for Primary and Secondary Objectives ............................ 99
Table 12 Mean Fold Increase in the Total Tumor Mutation Burden (TMB) in 
Circulating Free DNA (cfDNA) for Responders Compared to Non -
responders With 80% and 90% Power to Detect a Coefficient for cfDNA 
TMB Greater Than Zero for Varying Objective Response Rates (ORR) ...[ADDRESS_977278]: MK 3475 SCH 900475 12
PROTOCOL/AMENDMENT NO.: [ADDRESS_977279]: MK 3475 SCH 900475 13
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase II Trial to Investigate Genetic Markers of Response to 
Pembrolizumab (MK -3475, SCH 900475) Combined with Chemotherapy as a First -line 
Treatment for Non -Small Cell Lung Cancer (KEYNOTE- 782)
Short Title: Biomarkers of Response to Pem brolizumab Combined with Chemotherapy in 
Non- Small Cell Lung Cancer (KEYNOTE- 782) 
Acronym: KEYNOTE -782
Hypotheses, Objectives ,and Endpoints :
Participants with Stage IV nonsquamous NSCLC without prior systemic treatment will be 
treated with standard of care pembrolizumab combined with platinum -doublet chemotherapy 
for 4cycles, then pembr olizumab plus pemetrexed maintenance for up to 31 additional 
cycles .  The platinum doublet would be pemetrexed plus the investigator’s choice of either 
cispl atin or carboplatin.
Objectives /Hypothesis Endpoints
Primary Objective
•Objective:   To evaluate if total baseline 
tumor mutation burden (TMB) in cfDNA 
is predictive of objective response per 
Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST 1.1) by [CONTACT_716998] . •Objective response (OR):  Complete 
response (CR) or partial response (PR)
Secondary Objectives
Objective: To evaluate if total baseline 
TMB in cfDNA is predictive of 
progression -free survival (PFS)per 
RECIST 1.1 by [CONTACT_716999] ( OS)by [CONTACT_717000]. •PFS is defined as the time from the start 
of treatment to the f irst documented 
progressive disease (PD) or death due to 
any cause, whichever occurs first. 
•OS is defined as the time from the start 
of treatment to death due to any cause.
•Objective:  To evaluate the safety and 
tolerability of pembrolizumab + 
investigator choice chemo therapy .•Adverse events ( AEs)
•Discontinu ations due to AEs.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 14
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Overall Desig n:
Study Phase Phase 2
Primary Purpose Treatment
Indication Non-Small Cell Lung Cancer
Population Male/Female participant s with nonsquamous NSCLC who 
have not received prior systemic chemotherapy treatment 
for stage IV NSCLC, are at least 18 years of age ,and in 
whom epi[INVESTIGATOR_3506] (EGFR -), 
anaplastic lymphoma kinase (ALK -), c-ros oncogene 1 
(ROS1), or B is oform of rapi[INVESTIGATOR_11907] 
(B-RAF) -directed therapy is not indicated will be enrolled 
in this trial.
Study Type Interventional
Intervention Model Single Group
This is a multi- sitestudy.
Type of Control No treatment control
Study Blinding Unblinded Open -label
Masking No Masking
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately [ADDRESS_977280] participant’s last 
study- related telephone call or visit.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 15
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Number of Participant s:
Approximately 100 participants will be enrolled in this study as described in Section 9. 9.
Intervention Groups and Du ration :
Interventio
n GroupsIntervention 
Group Name [CONTACT_151578] .Regimen/ 
Treatment 
Period/ Use
1Pembrolizumab 200 mg Q3WIV 
infusionDay 1 of 
each 21 day 
cycleSOCa
Pemetrexed 500 mg/m2Q3WIV 
infusionDay 1 of 
each 21 day 
cycleSOC
Carboplatin
OR
CisplatinAUC 
5mg/mL/m
in
75mg/m2Q3WIV 
infusionDay 1 of
each 
21-day 
cycle for 
4cycles 
(Cycles 1 –
4)SOC
Abbreviations: IV  intravenous; Q3W  every 3 weeks; SOC  standard of care.
aMay not be SOC in some countries.
Total 
Number1
Duration of 
Partici -
pationEach participant will participate in the study from the time the participant signs 
the Informed Consent F orm (ICF) through the final protocol -specified contact.
After a screening phase of up to 28 days , each participant will be assigned to 
receive study in tervention until disease progression is radiographically 
documented and , when clinically appropriate, confirmed by [CONTACT_264806] 1.1 for immune -based 
therapeutics (iRECIST) for participants treated with pembrolizumab, 
unacceptable adverse event(s) (AEs), intercurrent illness that prevents further 
administration of treatment, investigator’s decision to discontinue the 
participant, noncompliance with study intervention or procedure requirements or 
administ rative reasons requiring cessation of treatment, or until the participant 
has received 35 administrations of pembrol izumab (approximately 2 years).
After the end of treatment, each participant will be followed for the occurrence 
of AEs and spontaneously re ported pregnancy as described under Section 8.4.
Participants who discontinue for reasons other than radiographic disease 
progression will have post -treatment follow -up imaging for disease status until 
disease progression is documented radiographically per RECIST 1.[ADDRESS_977281] (for participants treated with 
pembrolizumab), initiating a non- study cancer treatment, withdrawing consent, 
or becoming lost to follow -up. All participants will be followed by [CONTACT_717001], withdrawal of consent, or the end of the study.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 16
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Study Governance Committees:
Steering Committee Yes
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 9.
1.[ADDRESS_977282]: MK 3475 SCH 900475 17
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
1.3 Schedule of Activities (SoA)
Table 1 Study Schedule of Activities
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977283] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
Administrative Procedures
Informed Consent X XAdditional consent 
is required at disease 
progression
Informed Consent for Future 
Biomedical Research (optional)X
Participant Identification Card XUpdate card once 
participant is
allocated .
Inclusion/Exclusion Criteria X
Demographics and Medical 
HistoryX
Prior/Concomitant Medication 
Review (including any prebiotic 
or probiotic use )X X X X X X X X X X XConcomitant 
medications may 
need to be reported 
beyond [ADDRESS_977284]: MK 3475 SCH 900475 18
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977285] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
Subsequent Antineoplastic 
Therapy StatusX X X
Survival StatusParticipants may be 
contact[CONTACT_717002].
Study Treatment Administration -
Pembrolizumab 200 mgX X X X X X X Pembrolizumab 
dosed Q3W .
Pemetrexed 500 mg/m2X X X X X X XParticipants may 
receive maintenance 
pemetrexed at the 
discretion of the 
investigator if 
participant 
discontinues 
treatment with 
pembrolizumab
during the study .
Carboplatin AUC 5 
OR
Cisplatin (75 mg/m2)X X X XDosed Q3W forthe 
first4 cycles.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 19
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977286] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
Clinical Procedures / Assessments
Review Adverse Events X X X X X X X X X XReport non serious 
AEs occurring 
within [ADDRESS_977287]: MK 3475 SCH 900475 20
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977288] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
Laboratory Procedures / Assessments: Analysis Performed by [CONTACT_717003] 
βHCG [ADDRESS_977289] dose in study. 
Pregnancy testing 
will be performed 
every cycle during 
the treatment period
and at end of 
treatment as 
described in Section 
10.5.3 , and as 
required locally.
PT/INR and aPTT/PTT XPerform eligibility 
labs within 10 days 
prior to C1 D1. 
Hepatitis B & C Serology XHepatitis B surface 
antigen, HBV DNA, 
HCV RNA (or HCV 
antibody if HCV
RNA is not the local 
SOC). May use 
central lab only if 
local lab is not 
capable. Only 
required if mandated 
by [CONTACT_717004] y.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 21
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977290] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977291]: MK 3475 SCH 900475 22
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977292] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977293] 
radiographically 
confirmed Partial 
Response (PR), at 
second 
radiographically 
confirmed PR, at 
first 
radiographically 
confirmed Complete 
Response (CR) , and 
at radiographically 
or clinically 
confirmed 
Progressi ve Disease
(PD).
06FWC3
CCI
0833R8
PRODUCT: MK 3475 SCH 900475 23
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977294] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977295] 
radiographically 
confirmed Partial 
Response (PR), at 
second 
radiographically 
confirmed PR, at 
first 
radiographically 
confirmed Complete 
Response (CR) , and 
at radiographically 
or clinically 
confirmed 
Progressive Disease
(PD).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 24
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977296] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977297]: MK 3475 SCH 900475 25
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977298] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977299] 
radiographically 
confirmed Partial 
Response (PR), at 
second 
radiographically 
confirmed PR, at 
first 
radiographically 
confirmed Complete 
Response (CR), and 
at radiographically 
or clinically 
confirmed 
Progressi ve Disease
(PD).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 26
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977300] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977301] 
dose of therapy 
C1D1 . A single 
stool collection
within 5 days prior 
to each of the 
following study 
visits: C2D1, 
C4D1, C12D1 ,and 
atradiographically 
or clinically 
confirmed 
Progressi ve Disease
(PD). Final 
collection may be 
returned to clinic at 
30day FU visit if it 
cannot be provided 
at progression .
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 27
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977302] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
Tumor Tissue Collection
Newly Obtained/Archival Tissue 
Sample or B iopsy for Biomarker 
Analysis , such as : WES, RNA, 
genetic analysis , and exploratory 
biomarkersXMay use archival 
tissue sample that 
was obtained prior 
to screening period 
as part of the 
participant’s 
standard care. If 
archived tissue of 
sufficient quality is 
not available ,fresh 
core biopsy is 
required. Newly 
obtained tumor 
tissue may be 
obtained within 90 
days of treatment 
initiation. Fine 
needle aspi[INVESTIGATOR_1516] 
(FNA) samples will 
not be accepted .
EGFR, ALK, BRAF, and ROS 
Molecular StatusXMay send tumor 
tissue to central lab 
for molecular testing 
if status is unknown 
and cannot be 
determined locally.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 28
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977303] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± [ADDRESS_977304] 
Assessments (see Section 8.2.1)X X X See note X XPerform imaging at 
Baseline, C3D1, 
C5D1, C8D1, , then 
Q9W through Week 
48, then Q12W 
subsequently (all
imaging after 
baseline has a ±7
daywindow). 
Schedule should be 
followed regardless 
of treatment delays.
If imaging was 
obtained within [ADDRESS_977305]: MK 3475 SCH 900475 29
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Trial Period
ScreeningTreatment Cycles (3 -week cycles)
EOTPost Treatment Notes
Visit/CycleC1
D1C2
D1C3
D1C4
D1C5
D1C6
D1Cycle 7 
and 
beyondSafety 
FUFollow -up 
VisitsSurvival 
FU
Scheduled Time Point and 
Window-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 At DC ±[ADDRESS_977306] DC
±7Q9W to 
Wk 48, 
then Q12W
± 14 daysQ12W
± 14 days
AE adverse events; ALK anaplastic lymphoma kinase ; aPTT activated PTT; AUC area under the curve; βHCG beta human chorionic gonadotropin; C c ycle; CBC 
 complete blood count; c fDNA  circulating free DNA; D d ay; DC discontinuation; DNA  deoxyribonucleic acid; ECG  Electrocardiogram; ECOG Eastern 
Cooperative Oncology Group; EGFR epi[INVESTIGATOR_3506]; EOT  end of treatment; FT3 free T3; FT4 free thyroxine; FU  follow up;HBV hepatitis B 
virus; HCV  hepatit is C virus; HIV  human immunodeficiency v irus; INR international normalized ratio; IVRS interactive voice response system ; iRECIST modified 
Response Evaluation Criteria in Solid Tumors 1.1 for immune based thera peutics; KRAS  a proto oncogene derived from Kirsten RAt Sarcoma virus; NSCLC nonsmall 
cell lung cancer; PDL1 programmed cell death ligand 1; PI [CONTACT_22660]; PT prothrombin time; PTT partial thromboplastin time ; Q  Every; 
RECIST Response Evaluation Criteria in Solid Tumors; RNA  ribonucleic acid; ROS 1 c ros oncogene 1 ; SAE serious adverse event; SOC standard of care; 
T3 triiodothyronine; TSH thyroid stimulating hormone; W/Wk Week; WES whole exome sequencing ; WOCBP women of childbearing potential.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 30
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
2 INTRODUCTION
2.1 Study Rationale
Rational efor the Trial and Selected Patient Populatio n
Multiple programmed cell death 1 (PD -1) receptor/programmed cell death ligand 1 (PD -L1)-
based combination therapi[INVESTIGATOR_716982].  However, it is not clear which 
patients are most likely to respond to which pembrolizumab- based combinations .  This study 
will evaluate the value of TMB , as measured by [CONTACT_717005], in predicting the response to 
pembrolizumab andchemotherapy in NSC LC, assess the utility of cfDNA as an emerging 
technology that can allow exploration of the mechanisms of progression on and resistance to 
pembrolizumab and chemotherapy , and assess the role of the metagenomics (microbiome) 
and metabolomics in response to pembrolizumab + chemotherapy in NSCLC . 
The global incidence of lung cancer was 1.8 million in 2012, resulting in an estimated 
1.6million deaths [World Health Organization 2012] . In the [LOCATION_002], the 2016 
estimated incidence of new diagnoses was 224,400 and estimated number of deaths was 
158,100 [National Cancer Institute 2016] . NSCLC represents approximately 80% to 85% of 
all lung cancers. Of the patients with NSCLC, tumor histology is approximately 4 6% 
adenocarcinoma, 16 % squamous, 5%other (including neuroendocrine ), and the rest, “not 
otherwise specified” [Sulpher, J. A., et al 2013] .
The standard of care (SOC) for metastatic NSCLC has changed in recent years with the 
development of imm unotherapy agent s. Two important trials, KEYNOTE -[ADDRESS_977307]-line 
setting versus chemotherapy.  In the Phase 3 study KEYNOTE -024, pembrolizu mab, a PD -1 
receptor inhibitor, showed statistically significant increases in overall survival (OS) and 
progression -free survival (PFS) compared to SOC platinum -based chemotherapy for 
treatment -naïve participants with metastatic NSCLC whose tumors expressed high levels of 
PD-L1 (tumor pr oportion score [TPS] ≥50%) with no epi[INVESTIGATOR_3506] 
(EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberration s, leading to 
regulatory approval for this indication in the US and other countries around the world.
Approximately 30% o f patients with newly diagnosed, advanced NSCLC have tumors that 
highly express PD- L1 to a TPS ≥50% [Reck, M., et al 2016] .
KEYNOTE -[ADDRESS_977308] -line 
therapy in patients with advanced or metastatic NSCLC that expresses PD- L1 in ≥1% of 
tumor cells .  In 2018 ,an interim analysis conducted by [CONTACT_700017] (DMC) demonstrated that treatment with pembrolizumab resulted in significantly 
longer OS than platinum -based chemotherapy (carboplatin plus paclitaxel or carboplatin plus 
pemetr exed) in patients with a PD -L1 TPS ≥1%. As pa rt of a prespecified anal ysis plan, OS 
was sequentially tested and was significantly improved in patients with a TPS ≥50%, with a 
TPS ≥20%,and then in the entire study population with a TPS ≥1%[Lopes, G., et al 2018] . 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 31
PROTOCOL/AMENDMENT NO.: [ADDRESS_977309]-linemetastatic NSCLC has been 
platinum -doubl et chemotherapy. Studies evaluating different pembrolizumab combinations 
in anti -PD-1/PD -L1naïve participants have shown preliminary evidence of clinical activity 
in participants with recurrent and/or metastatic disease. To evaluate the activity of the 
combination of pembrolizumab and chemotherapy , 2pi[INVESTIGATOR_716983],
KEYNOTE -021 and the follow -up study, KEYNOTE- 189 (see S ection 2.2.2) .  In the Phase 
1/2 study K EYNOTE -021 Cohort G, pembrolizumab plus pemetrexed and carbop latin 
showed statistically significant increases in objective response rate (ORR) compared to 
pemetrexed and carboplatin alone in participants with nonsquamous advanced NSCLC, 
regardless of PD- L1 status, although t he ORR was higher in the TPS ≥50% subgroup. Thes e
results established pembrolizumab plus chemotherapy as an efficacious option for first -line 
therapy in patients with NSCLC; these findings were further evaluated in the Phase 3 study 
KEYNOTE -189 (nonsquamous histology ).  In KEYNOTE- 189, pembrolizumab plus
investigator choice platinum agent and pemetrexed chemotherapy had a statistically
significant increase in OS over the platinum agent and pemetrexed alone in advanced 
NSC LC[Lopes, G., et al 2018] .
However, for these studies not all NSCLC patients have shown benefit from anti- PD-[ADDRESS_977310], including mi crobiome, or the tumor microenvironment. Moreover , many 
patients ultimately progress, indicating the need for identifying those mechanisms to increase
and maintain benefi t. Such resistance mechanisms are likely to be heterogeneous and multi -
factorial; therefore, identifying new biomarkers of response to differentiate potential 
responders or non -responders will enable further development of more sophisti cated patient 
selection criteria and potential combination therapi[INVESTIGATOR_014], either up front or upon progression. 
Furthermore, taking a more holistic approach, markers of a microbiome conducive or 
detrimental to PD -1 therapy may point to possible microbiome augme ntation or modulation 
to enhance anti -PD-1 therapy and/or reduce associated drug toxicity. To elucidate this 
biology ,it is best considered where PD -[ADDRESS_977311] -line NSCLC [Reck, M., et al 2016] .  We are interested 
in exp loring other potential markers of PD -[ADDRESS_977312] demonstrated that treatment with a combination of 
pembrolizumab and chemotherapy has clinical benefit over chemotherapy alone [Gandhi, L., 
et al 2018] .Chemotherapy adds another layer of complexity to PD -1 intervention due to its 
multitude of effects on the patient’s physiology, tumor, and immune s ystem .
In return , other elements may modulate chemotherapy function such as the microbiome ,
which comprises the eukaryote and prokaryote microorganisms that occupy distinct 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 32
PROTOCOL/AMENDMENT NO.: [ADDRESS_977313] ed by [CONTACT_717006]. The m icrobiome has been shown to 
modulate the function of a variety of chemotherap iesthrough immune -and non -immune -
mediated mechanisms.  
Pembrolizumab has been combined with chemotherapy in several tu mor ty pes,yet little is 
known about the biological mechanisms of the interactions between these therapi[INVESTIGATOR_014]. The 
deep interrogation of response and resistance mechanisms to pembrolizumab in combination 
with chemotherapy has the potential to establish tumor -agnostic markers of response and/or 
resistance. 
Understanding the relationship between tumor genetics, the immun e system, 
microbiome, 
and response to anti-PD-[ADDRESS_977314] from normal tissue to activate the 
immune system and induce an efficient ant itumor response. Tumor -mutated specific antigens 
(neoantigens) are major tumor rejection antigens [Schumacher, T. N. 2015 ] [Castle, J. C., et 
al 2012] . The recent development of innovative deep sequencing technolo gies (at an 
affordable cost) along with advances in bioinformatics has enabled systemic analysis of 
nonsynonymous somatic TMB and identification of potentially immunogenic neoantigens. 
The genetic landscape and the full spectrum of genomic alterat ions in each individual tumor 
provide t he guidance for personalized cancer immunotherapy [Yuan, J. 2016] .
Two pi[INVESTIGATOR_716984]- specific cluster of differentiation ( CD)8+ T- cells associated with tumor 
response [Matsushita, H., et al 2012] [Castle, J. C., et al 2012] . Several clinical studies 
demonstrated the feasibility and importance of understanding the immunogenicity of 
neoantigens and their potential clinical application in patients treated with tumor -infiltrating 
lymphocyte adoptive cell therapy [Robbins, P. F., etal 2013] [Tran, E. 2014] [Linnemann, 
C., et al 2015] . Tumor mutational burden was associated with clinical outcome to immune 
checkpoint blockade cancer immunotherapy in patients with advanced melanoma and
NSCLC [Snyder, A., et al 2014] [Rizvi, N. A., et al 2015] [Van Allen, E. M., et al 2015] . 
Patients with mismatch repair deficient tumors likewise had high rates of clinical response to 
PD-1 blockade [Le , D., et al 2015] .  The recent [ADDRESS_977315]: MK 3475 SCH 900475 33
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
microsatellite instability ( MSI)-high tumors highlights this relationship between DNA repair 
abrogation, neoantigens, and res ponse to checkpoint inhibitors.
Recent data ha veshown a relationship between TMB and monotherapy response to 
pembrolizumab in NSCLC [Rizvi, N. A., et al 2015].  Checkmate [ADDRESS_977316]-lineNSCLC. The 
statistical design was modified during trial execution to include TMB forpatient stratification
independent of PD- L1-status . Selective trial data were presented at the 2018 annual 
American Association for Cancer Research meeting [Hellmann, M. D., et al 2018] and 
indicated that the combination of a cytotoxic T -lymphocyte -associated protein 4 ( CTLA -4)
inhibitor ,ipi[INVESTIGATOR_125] ,and the PD -1 inhibitor nivolumab had superior PFS compared to 
chemotherapy for participants with high TMB defined at >[ADDRESS_977317]-line
nonsquamous NSCLC setting. TMB has not been prospectively interrogated in this 
population as an exploratory marker ,and several significant questions remain around 
relationship between PD -L1 status, TMB ,and whether TMB itself is predictive of response
in the setting of an anti -PD-1/PD -L1 agent and chemotherapy.
This trial is intended to extend these studies to investigate TMB as one of several exploratory 
genetic markers for response to pembrolizumab in combination with chemotherapy in the 
first-lineNSCLC setting.
Tumor Cell -Free DNA An alysis
Tumor genetics and TMB have been historically interrogated using next -generation 
sequencing technologies using formalin- fixed paraffin embedded tissue (FFPE) ,with DNA 
sequencing being whole genome, whole exome, or defined gene panels. For many tumor 
types ,biopsies have inherent risk to the patient, notwithstanding patient logistical and 
financial costs. While biopsies for diagnosis do constitute a standard of care ,for a variety of 
technical reasons ,including having reliable tissue for DNA sequencing, blood -based markers 
offer a variety of advantages.  Furthermore ,biopsies are usually undertaken at diagnosis ,
whereas blood- based markers have the advantage of being interrogated over the course of 
therapy and importantly at progression .
Through mechanisms that are not well understood, small fragments of tumor DNA appear in 
systemic circulation. An increasing body of evidence demonstrates that these fragments, 
known as cell- free circulating tumor DNA (cfDNA), directly encode genetic features of the 
tumors from which they are deri ved(http://www.grail.com) . cfDNA can be interrogated at 
the whole -genome level or using defined gene panels. The latter offers several advantages ,
including cost and reduced s equencing and analysis time , both of which are important in a 
clinical setting. Gene panels can be constructed to interrogate several features of a tumor’s 
genetics and can obtain the same depth of genetic information as can be obtained from 
whole -genome a nalyses.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 34
PROTOCOL/AMENDMENT NO.: [ADDRESS_977318] 
response and/or progression is constrained by a defined time point analysis of the tumor -
immune interaction, which is not relevant to the stochastic relationship between an evolving 
tumor and the immune system. Therefore ,a blood -based cfDNA assay offers the advantage 
as a read- out of these temporal changes ,with the prospect of kinetic assessment of tumor 
fraction cfDNA being predictive for early response and/or progression to immunotherapy. In 
addition, the ability to assess temporal changes in tumor genetics will give insight into tumor 
clonal evolution and immune editing of specific neoantigens.
Therefore , ascfDNA represents the genomic diversity of cancer throughout the body , 
cfDNA -based tests have the potential to deliver sensitive and specific tests for early cancer 
detection, analysis of TMB and tumor genetics, mechanisms of resistance to imm unotherapy, 
and importantly, determination of tumor response to therapy. This trial will assess these 
exploratory genetic markers ,including TMB ,in collaboration with GRAIL Inc. 
(http://www.grail.com) ,a company specializing in tumor cfDNA analysis. These analyses 
will be performed using a proprietary gene panel and bioinformatics pi[INVESTIGATOR_716985] a 
focused assessment of NSCLC genetics and immune activity. 
This study will investigate the utility of cfDNA technology to assess tumor genetics as 
predictive for response or resistance to pembrolizumab plus chemotherapy in study 
participants with stage IV NSCLC without prior systemic therapy. The study will also 
investigate other exploratory cellular and genetic markers of immune response.
Microbiome Modulation of the Immune System and Immunotherapy
The human body is host to large numbers of bacteria and other microorganisms, primarily 
colonizing epi[INVESTIGATOR_716986]. 
Microbiome components have both local and physiological effects that are mediated via 
microbiome -immune co- evolution and microbiome production of metabolites [Belkaid, Y. 
2017]. These commensals play an important homeostatic role in a variety of human body 
systems, including the immune system and endocrine systems . The microbiota play a 
fundamental role in the induction, evolution, function, and modulation of the host immune 
system. Likewise, the host immune system has evolved mechani sms to maintain this 
symbiotic relationship with the microbiome. The maintenance of this communication allows 
the induction of protective responses to pathogenic organisms and the utilization of immune 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 35
PROTOCOL/AMENDMENT NO.: [ADDRESS_977319] range of immune functions [Haase, S., et al 2018] .  The lung is one 
such tissue impacted by [CONTACT_717007] [Shukla, S. D., et al 2017]. Chronic 
respi[INVESTIGATOR_3748], namely asthma, chronic obstructive pulmonary disease (COPD) and 
cystic fibrosis ,all have been demonstrated to be impacted by [CONTACT_226698] (reviewed in 
[Shukla, S. D., et al 2017] [Lloyd, C. M. 2017] ). The gut lung cross -talk is considered to be 
mediated by [CONTACT_717008], microbiome -generated metabolites, and patrolling immune 
cells. This relationship between the systemic effects of the gut microbiome and the immune 
system suggest sa combined impact on the development of cancer and its evasion of the 
immune system.  
The microbiome may modulate systemic T cell- mediated tumoricidal activity, as 
administration of antibiotics severely reduced the efficacy of adoptive T -cell transfer in 
several mouse models of cancer [Luo, A., et al 2017] .  The microbiome -mediated modulation 
of the immune system impacts cancer at all of its developmental stages, including 
development, elimination, equilibrium, and escape [Zitvogel, L., et al 2018] [Kim, C. H. 
2018] [Rea, D., et al 2018] . Some tumor sthemselves have been reported to have a resident 
microbiome population ,suggesting that effect s may sometimes be more direct [Hooper, S. J., 
et al 2007] [Chanudet, E., et al 2007] [Hubbard, A. L., et al 1998] [Silva- Valenzuela, C. A., 
et al 2016] .Microorganism presence in tumor tissue can be directly related to tumorigenesis , 
as exemplified by H elicobacter pylori in gastric cancer [Wroblewski, L. E., et al 2010] ,or 
may represent a coincidental infection.
However, our understanding of this biological interaction between microbiome and tumor 
immunology is limited.  Evidence suggests for some cancers ,such as GI cancer, that gut 
dysbiosis is a direct contributing factor to cancer development and immune evasion [Meng, 
C., et al 2018] .  Ident ifying defined mechanisms of microbiome -induced immune evasion of 
cancer will help to determine how that microbiome may also be directed to be “pro-
tumorigenic ” versus “tumor -protective”.  Furthermore ,the microbiome has an additional 
cancer -related effect ,which is modulation of the effectiveness of chemotherapy and 
immunotherapy. So, identifying how to alter microbiome elements to increase therapy 
effectiveness may be a new element in cancer therapy. 
The recent advances in the use of immunotherapy in the first -linelung cancer space have
indicated the rationale for combination of chemotherapy with immune agents. The concept 
that the microbiome may independently modulate these modalities individually a nd in 
combination indicates a need to understand these effects. Evidence from mouse models 
suggests links between the effectiveness of platinum -based cytotoxic compounds and the 
microbiome [Iida, N., et al 2013] [Alexander, J. L., et al 2017] . However ,there are limited 
clinical data on microbiome and standard of care chemotherapi[INVESTIGATOR_014]. 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 36
PROTOCOL/AMENDMENT NO.: [ADDRESS_977320] links between various bacterial genera and T -cell 
components associated with checkpoint inhibitors [Vetizou, M. , et al 2015] .  Three recent 
investigations into the microbiome and the PD -1/PD-L1 axis have provided clinical data that 
the gut microbiome modulates the response to inhibitors of PD -1/PD-L1 axis
[Gopalakrishnan, V., et al 2018] [Matson, V., et al 2018] [Routy, B., et al 2018] . Overall, 
they indicated that a healthier, highly diverse microbiota and the presence of certain bacterial 
species favor the establishment of an anti -tumor immune response at baseline that may be 
enhanced by [CONTACT_16682] -PD-[ADDRESS_977321] cancer 
immunity. Presumably, the effects on the immune system may not be wholly dependent on 
the bacterial composition per se but more potentially on the metabolites they produce
[Cummings, J. H., et al 1987] [Rooks, M. G. 2016] [Stockinger, B., et al 2014]. So,
unde rstanding the element of bacterial -produced metabolites through metabolomics analysis 
in conjunction with microbiome assessment will help us to further understand the 
relationship with response to anti -PD-[ADDRESS_977322] perturbed the microbiota due to the therapy itself, AEs such as GI  toxicity, 
or the management of AEs such as use of antibiotics in infections.
2.2 Background
Pembrolizumab is a potent humanized immunoglobulin (Ig)G4 monoclonal antibody (mAb) 
with high specificity of binding to the PD- 1 receptor, thus inhibiting its interaction with 
PD-L1 and programmed cell death ligand 2 (PD -L2).  Based on preclinical in vitro data, 
pembrolizumab has high affinity and potent receptor blocking activity for PD -1.  
Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as 
an intravenous (IV) immunotherapy for advanced malignancies.  Keytruda® 
(pembrolizumab) is indicated for the treatment of patients across a number of indications. For 
more details on specific indications, r efer to the Investigator’s Brochure (IB).
In this study, pembrolizumab will be administered in combination with pemetrexed and 
either cisplatin or carboplatin .   Refer to the prescribing information for cisplatin, carboplatin, 
and pemetrexed.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 37
PROTOCOL/AMENDMENT NO.: [ADDRESS_977323] immune surveillance function in controlling outgrowth of neoplastic 
transformations has been known for decades [Disis, M. L. 2010] .  Accumulating evidence 
shows a correlation between tumor -infiltrating lymphocytes in cancer tissue and favorable 
prognosis in various malignancies.  In particular, the presence of CD8+ T -cells and the ratio 
of CD8+ effector T -cells to FoxP3+ re gulatory T -cells (T -regs) correlates with improved 
prognosis and long -term survival in solid malignancies, such as ovarian, colorectal, and 
pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and renal cell carcinoma.  
Tumor -infiltrating lymph ocytes can be expanded ex vivo and reinfused, inducing dur able 
objective tumor responses in cancers such as melanoma [Dudley, M. E., et al 2005] [Hunder, 
N. N., et al 2008] .
The PD -[ADDRESS_977324] hijacked by [CONTACT_55548].  The normal function of PD- 1, expressed on the cell surface of activated 
Tcells under healthy conditions, is to down -modulate unwanted or excessive immune 
responses, including autoimmune reactions. PD -1 (encoded by [CONTACT_13228]1) is an Ig 
superfamily member related to CD28 and CTLA -4 that has been shown to negatively 
regulate a ntigen receptor signaling upon engagement of its ligands (PD -L1 and/or PD -L2) 
[Greenwald, R. J., et al 2005] [Okazaki, T., et al 2001] . 
The structure of murine PD -1 has been resolved [Zhang, X., et al 2004] .  PD -1 and its family 
members are type I transmembrane glycoproteins containing an Ig -variable type (IgV type) 
domain responsible for ligand binding and a cytoplasmic tail responsible for the binding of 
signaling molecules.  The cytoplasmic tail of PD -1 contains 2 tyrosine -based signaling 
motifs, an immunoreceptor tyrosine -based inhibition motif, and an immunoreceptor tyrosine -
based switch motif.  Following T -cell stimulation, PD -1 recruits the tyrosine phosphatases, 
SHP-1 and SHP -2, to the immunoreceptor tyrosine -based switch motif within its cytoplasmic 
tail, leading to the dephosphorylation of effector molecules such as CD3 zeta (CD3ζ), protein 
kinase C -theta (PKCθ), and zeta -chain -associated protein kinase (ZAP70), which are 
involved in th e CD3 T- cell signaling cascade [Okazaki, T., et al 2001] [Chemnitz, J. M., et al 
2004] [Sheppard, K- A, et al 2004] [Riley, J. L. 2009].  The mechanism by [CONTACT_13209] -[ADDRESS_977325] from, that of CTLA -4, because 
both molecules regulate an overlap pi[INVESTIGATOR_77971] [Parry, R. V., et al 2005] 
[Francisco, L. M ., et al 2010] .  As a consequence, the PD -1/PD -L1 pathway is an attractive 
target for therapeutic intervention in NSCLC.
Comp leted Clinical Studies
Sixcompleted, company -sponsored, clinical studies were conducted to evaluate the efficacy 
of pembrolizum ab monotherapy and pembrolizumab combination therapy in the treatment of 
NSCLC: KEYNOTE- 001, KEYNOTE- 010, KEYNOTE -021, KEYNOTE- 024, 
KEYNOTE -042, and KEYNOTE- 189.  Several additional studies are in progre ss.  Refer to 
the current pembrolizumab IB for a description of KEYNOTE- 001 and KEYNOTE -010.  
The results of KEYNOTE- 010 indicate that in previously treated participants with NSCLC 
with PD-L1 TPS ≥1%, and disease progression following platinum -containing 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 38
PROTOCOL/AMENDMENT NO.: [ADDRESS_977326] docetaxel chemotherapy. Furthermore, the PD -L1 selection 
employed in KEYNOTE -010 identified participants more likely to benefit from 
pembro lizumab and resulted in favorable HR in OS compared to docetaxel.
Overall, the results from KEYNOTE -001 and KEYNOTE -010 demonstrated that 
pembrolizumab provided substantial, clinically meaningful benefits in OS, PFS, and ORR in 
participants with NSCLC who progressed after platinum -containing chemotherapy and 
whose tumor cells expressed PD-L1. The 2 key clinical studies for this trial population are 
KEYNOTE -021 Cohort G and KEYNOTE- 189.
KEYNOTE –021
In the Phase 1 /2Cohort A of KEYNOTE- 021, 25 participant s with treatment -naïve, 
advanced/metastatic NSCLC, regardless of PD- L1 expression and without treatable EGFR or 
ALK aberrations, were treated with 4 cycles of carboplatin, paclitaxel, and pembrolizumab 
(randomized 1: 1 to 2 mg/kg or 10 mg/kg) followed by [CONTACT_79911] Q3W [Langer, C. J., 
et al 2016] . The primary endpoint of the cohort was to determine the recommended Phase 2 
dose for pembrolizumab in combination with chemoth erapy in participant s with unresectable 
or metastatic NSC LC.
No dose -limiting toxicities were observed, no treatment- related deaths occurred, and no 
treatment -related discontinuations occurred. Grade 3/4 AE were observed in 56% of 
participant s and potentia l irAEs were observed in 16% of participant s.
After a median duration of follow -up of 13 months (range, 2 -21 months), the confirmed ORR 
was 52% (13/25; 95% CI: 31 to 72) per blinded independent central review ( BICR ). Median 
PFS was 10.3 months (95% CI: 3.7 to not reached [NR]) per BICR and OS was NR ( 95% CI: 
11.0 to NR ). Responses were seen in both PD -L1-positive and PD -L1-negative participants 
[Gadgeel, S., et al 2016]
In the Phase [ADDRESS_977327]- line treatment of participants with 
metastatic nonsquamous NSCLC, contingent upon verification and description of clinical 
benefit in a confirmatory study [Langer, C. J., et al 2016] .
Cohort G include dparticipants with treatment -naïve, nonsquamous, stage IIIB/IV NSCLC, 
irrespective of PD -L1 expression and without treatable EGFR mutations or ALK 
translocations, randomized 1:[ADDRESS_977328]: MK 3475 SCH 900475 39
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
The cohort enrolled 123 participants ,with 60 randomly assigned to the pembrolizumab plus 
chemotherapy armand 63 to the chemotherapy alone group. For the primary endpoint of 
ORR, 33/60 participants (55%; 95% CI :42 to 68) in the pembrolizumab plus chemotherapy 
group achieved an objective response compared with 18/63 participants (29%; 95% CI :18 to 
41) in the chemotherapy -alone group (estimated treatment difference: 26% [95% CI :9 to 
42]; p 0.0016).
Progression -free survival was significantly longer with pembrolizumab plus chemo therapy 
compared with chemotherapy alone (HR 0.53 [95% CI :0.31 to 0.91]; p 0.010). Median PFS 
was 13.0 months (95% CI :8.3 to NR ) for pembrolizumab plus chemotherapy and 8.9 months 
(95% CI :4.4 to 10.3) for chemotherapy alone. At the time of data cutoff, no difference in 
survival was noted between treatment groups (HR 0.90 [95% CI :0.42 to 1.91]), though the 
survival analysis may be premature and participants progressing on the chemotherapy -only 
arm were permitted to crossover to pembrolizumab monotherapy on study as well as receive 
immunotherapy subsequently.
Treatment -related AEs occurred in 55/59 (93%) participants in the as- treated pembrolizumab 
plus chemotherapy group and 56/62 (90%) participants in the as -treated chemotherapy alone 
group, including 23 (39%) and 16 (26%) participants, respectively, who had events of 
Grade 3 or worse severit y. The rate of treatment discontinuation because of treatment- related 
AEs was similar between groups, with 6/59 (10%) participants in the pembrolizumab plus 
chemotherapy group and 8/62 (13%) participants in the chemotherapy -alone group.
The addition of pembrolizumab to carboplatin and pemetrexed significantly improved the 
proportion of participants who achieved an objective response compared with carboplatin 
and pemetrexed alone in participants with chemotherapy -naïve, advanced nonsquamous 
NSCLC. In addition, this combination significantly prolonged PFS in this population. These 
data suggest that the combination of pembrolizumab, carboplatin, and pemetrexed pro vides a 
significant and clinically relevant improvement in antitumor activity compared with 
chemotherapy alone for treatment -naïve, nonsquamous, advanced NSCLC. These results 
subsequently led to the FDA- accelerated approval of the combination for the first- line 
treatment of participants with metastatic nonsquamous NSCLC, contingent upon verification 
and description of clinical benefit in a confirmatory study KEYNOTE -189.
KEYNOTE -189
KEYNOTE -189 is a Phase 3, randomized, double -blinded, active -controlled, mu lticenter 
study of pembrolizumab plus pemetrexed and platinum (carboplatin or cisplatin) versu s 
pemetrexed and platinum in participants with treatment -naïve, metastatic, nonsquamous 
NSCLC. The primary endpoint is PFS per RECIST 1.1 as assessed by [CONTACT_19377]. 
The results of the KEYNOTE- 189 demonstrated an OS benefit of p embrolizumab plus 
platinum -based doublet chemotherapy to platinum -doublet chemotherapy alone [Gandhi, L., 
et al 2018] . After a median follow -up of 10.5 months, the estimated survival at 12 months 
was 69.2% (95% CI :64.1 to 73.8) in the pembrolizumab -containing group versus 49.4% 
(95% CI :42.1 to 56.2) in the placebo -combination group, with a nHR for death 0.49 ( 95% 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 40
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
CI:0.38 to 0.64; p <0.001) .  There was an improvement in OS seen across all PD -L1 groups 
that were evaluated. The median PFS was 8.8 months (95% CI :7.6 to 9.2) in the 
pembrolizumab -containing group and 4.9 months (95% CI :4.7 to 5.5) in the placebo -
combination group, with a nHR for disease progression or death 0.52 (95% CI :0.43 to 0.64; 
p<0.001). The KEYNOTE- [ADDRESS_977329]-lineNSCL C treatment.
The overall response rate as sed by [CONTACT_557427] 47.6% (95 CI :42.6 to 52.5) in the 
pembrolizumab -combination group and 18.9% 95% CI :13.8 to 25.0) in the placebo -
combination group ( p<0.001 ). The disease control rate (the proportion of patients with a 
confirmed complete or partial respons e or stable disease) was 84.6% in the pembrolizumab 
combination group and 70.4% in the placebo -combination group. The median duration of 
response was 11.2 months (range, 1.1+ to 18.0+) in the pembrolizumab- combination group 
and 7.8 months (range, 2 .1+ to 1 6.4+) in the placebo -combination group . The response rate 
in the pembrolizumab- containing arm was higher in all categories of PD -L1 tumor proportion 
score, with the greatest difference in patients with TPS ≥50% ( 61.4% vs 22.9%) .
Adverse events of any cause regardless of attribution occurred in 99.8% of the patients in the 
pembrolizumab -combination group and in 99.0% of those in the placebo -containing group. 
The events were G rade 3 or higher in 67.2% and 65.8% of the patients, respectively. 
Discontinuation o
f all trials drugs because of AEs occurred in 13.8% of patients in the 
pembrolizumab -combination group and in 7.9% of the placebo -containing group. 
Discontinua tion of pembrolizumab and placebo were 20.2% and 10.4% ,respectively. 
These results have confirm ed that KEYNOTE -[ADDRESS_977330] 
demonstrated the increased clinical efficacy of pembrolizumab andplatinum -containing 
doublet chemotherapy versus platinum -containing doublet across all categories of PD -L1 
expression.   The data from KEYNOT E-021 and KEYNOTE -189 demonstrate there is still a 
need to understand the biology of resistance to PD -1 inhibitors and exploratory markers of 
pembrolizumab and chemotherapy response.
Ongoing Clinical Studies
[IP_ADDRESS] Pembrolizumab Studies
Pembrolizumab is under evaluation in participants with NSCLC as monotherapy and in 
combination with chemotherapy, immunotherapy, and targeted therapi[INVESTIGATOR_014]. A full list of 
ongoing company- sponsored studies can be found in the current IB of pembrolizumab.
[IP_ADDRESS] Ongoing Grail cfNA Biomarker Stu dies
There are 2 ongoing GRAIL -sponsored oncology studies using cfDNA to interpret tumor 
genetics.  [STUDY_ID_REMOVED] titled “The Circulating Cell- free Genome Atlas Study (CCGA)” is a 
study aimed at mappi[INVESTIGATOR_716987] -free tumor genome of early cancer patients. This study will 
collect biological samples from donors with a new diagnosis of cancer (blood and tumor 
tissue) and from donors who do not have a diagnosis of cancer (blood) in order to 
characterize the population heterogeneity in cancer and non -cancer partic ipants and to 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 41
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
develop and validate models for distinguishing cancer from non- cancer.  The purpose of the 
CCGA Study is to characterize the landscape of cell- free nucleic acid (cfNA) profiles in 
individuals with and without cancer , and develop an assay to detect early cancer in blood. 
The observational CCGA Study will enroll approximately 10,500 individuals with newly 
diagnosed cancer (treatment naïve) and approximately [ADDRESS_977331] development goals. The database, upon analysis, may be 
expanded to enroll additional individuals with specific cancers or without cancer. Initial 
results from a substudy of approximately 1650 participants from CCGA were presented at 
the 2018 Annual American Association for Cancer Resear ch Conference [Aravanis, A. A., et 
al 2018] .
[STUDY_ID_REMOVED] is an observation albreast c ancer study titled “The STRIVE Study: Breast 
Cancer Screening Cohort for Development of Assays for Early Cancer Detection”. The aim 
of this study is to use high- intensity sequencing of circulating cfNAs to support the 
develop ment of a testfor detection of invasive breast cancer. STRIVE is a multi -center, 
longitudinal, prospective, observational study that will enroll approximately 120,000 women 
at the time of their screening mammogram.      
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and effectiveness of an investigational medicine.   Results from KEYNOTE -189 
show that treatment with pembrolizumab plus platinum -doublet chemotherapy provides a 
substantial benefit in this patient population [Gandhi, L., et al 2018] .Additional details 
regarding specific benefits and risks for participants partic ipating in this clinical study may 
be found in the accompanying IB and informed consent documents.
[ADDRESS_977332] of care pembrolizumab combined with platinum -doublet chemotherapy 
for 4cycles, then pembr olizumab plus pemetrexed maintenance for up to 31 additional 
cycles .  The platinum doublet would be pemetrexed plus the investigator’s choice of either 
cisplatin or carboplat in.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 42
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Objectives Endpoints
Primary Objective
•Objective: To evaluate if total baseline 
TMB in cfDNA is predictive of objective 
response per RECIST 1.1 by [CONTACT_716998] .•Objective response (OR) :  Complete 
response (CR) or partial response (PR)
Secondary Objectives
•Objective: To evaluate if total baseline 
TMB in cfDNA is predictive of PFS per 
RECIST 1.1 by [CONTACT_717009] . •PFS is defined as the time from the start 
of treatment to the first documented 
progressive disease (PD) or death due to 
any cause, whichever occurs first.   
•OS is defined as the time from the start of 
treatment to death due to any cause.
•Objective:  To evaluate the safety and 
tolerability of pembrolizumab + 
investigator choice chemotherapy•AEs 
•Discontinu ations due to AEs
Tertiary/ Exploratory Objectives
•Objective:  To evaluate whether total 
baseline TMB in cfDN A or whole exome 
sequencing (WES) of tumor 
biopsy/sample is predictive of OR and
PFS per iRECIST 1.1 by [CONTACT_717010]•OR:  Complete response (CR) or partial 
response (PR)
•PFS is defined as the time from the start 
of treatment to the first documented PD 
or death due to any cause, whichever 
occurs first.   
•Objective:  To characterize kinetic 
profiles of tumor fraction in cfDNA and 
evaluate whether they are predictive of 
OR and PFS per RECIST 1.1 by 
[CONTACT_717011]•OR:  Complete response (CR) or partial 
response (PR)
•PFS is defined as the time from the start 
of treatment to the first documented PD 
or death due to any cause, whichever 
occurs first.   
•OS is defined as the time from the start of 
treatment to death due to any cause.
•Objective: To identify molecular 
(genomic, metabolic, and/or proteomic) 
biomarkers that may be indicative of 
clinical response/resistance, safety, 
pharmacodynamics activity, and/or the 
mechanism of action of chemotherapy or 
pembrolizumab•Germline genetic variation, genetic 
(DNA) mutations from tumor, tumor and 
blood RNA variation, proteomics and 
immunohistochemistry ( IHC), and other 
blood- derived biomarkers
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 43
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Objectives Endpoints
•Objective:  To estimate the concordance 
between baseline WES -based TMB of 
tumor biopsy or FFPE sample and 
baselineTMB in cfDNA•Baseline TMB in cfDNA (blood)
•WES -based TMB of tumor FFPE
biopsy/sample
•Objective:  To evaluate the impact of pre -
treatment (baseline) and on -treatment gut 
microbiome signatures associated with 
OR and PFS per RECIST 1.1 by 
[CONTACT_717011]•OR:  Complete response (CR) or partial 
response (PR)
•PFS is defined as the time from the start 
of trea tment to the first documented PD 
or death due to any cause, whichever 
occurs first.   
•OS is defined as the time from the start of 
treatment to death due to any cause.
•Objective: To evaluate whether
metabolomics components are associated 
with OR and PFS per RECIST 1.1 by 
[CONTACT_717011]•OR:  Complete response (CR) or partial 
response (PR)
•PFS is defined as the time from the start 
of treatment to the first documented PD 
or death due to any cause, whichever 
occurs first.   
•OS is defined as the time from the start of 
treatment to death due to any cause.
4 S TUDY DESIGN
4.1 Overall Design
This is a nonrandomized, multi- site, open-label study of pembrolizumab + platinum -doublet
chemotherapy (pemetrexed plus investigator’ s choice of either cisplatin or carboplatin) as 
first-line treatment in participants with stage IV NSCLC who have not previously received 
systemic therapy for their metastatic disease and in whom EGFR -,ALK -, B-RAF -, or ROS1 -
directed therapy is not indicated.  Treatment will include pembrolizumab combined with a 
platinum -doublet chemotherapy for 4cycles then pemb rolizumab plus pemetrexed 
maintenance for up to 31 additional cycles .  The platinum -doublet willbe pemetrexed plus 
the investigator’s choice of either cisplatin or carboplatin .
Participants will be evaluated with radiographic imaging to assess response to treatment at 
6weeks (42 ± 7 days) and 12 weeks (84 ± 7 days) and then every 9 weeks (63 ± 7 days) for 
the first 48 weeks and every 12 weeks (84 ± 7 days) subsequently.  Imaging will continue on 
this schedule until documented disease progression, unacceptable AE (s), intercurrent illness 
that prevents further administration of treatment, investigato r’s decision to discontinue the 
participant , participant withdraws consent, pregnancy of the participant, noncompliance with 
trial treatment or procedure requirements, or administrative reasons ,or initiation of a new 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 44
PROTOCOL/AMENDMENT NO.: [ADDRESS_977333] 1.1 (see Section 8.2) for 
determination of objective response of complete or partial response (CR or PR, respectively) 
and PFS . 
AE monitorin g will be ongoing throughout the study and graded in severity according to the 
guidelines outlined in the National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) v 4.0.
Study t reatment will continue until 35 administrations of pembr olizumab (approximately 
2years) , documented PD , unacceptable AEs, intercurrent illness that prevents further 
administration of treatment, investigator ’s decision to discontinue the participant, participan t 
withdraw al of consent, pregnancy of the participa nt, or administrative reasons requiring the 
cessation of treatment.  Optionally, participants with a confirmed CR who have received at 
least 8 cycles of pembrolizumab may discontinue treatment (Section 7.1).
All participants will be followed by [CONTACT_80058], withdrawal of consent, or 
the end of the study.
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.[ADDRESS_977334] the utility of TMB a nd other exploratory markers of response in a 
treatment -naïve nonsquamous NSCLC population .  The treatment regimen of pembrolizumab 
in combination with platinum -doublet chemot herapy has been previously tested with positive 
efficacy results in a randomized, P hase 3 trial, KEYNOTE- 189.
Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
[IP_ADDRESS].[ADDRESS_977335] is large 
and the therapy has an acceptable risk/benefit profile. The u se of RECIST 1.[ADDRESS_977336]: MK 3475 SCH 900475 45
PROTOCOL/AMENDMENT NO.: [ADDRESS_977337] 1.1 will be used when assessing images for efficacy measures and by [CONTACT_717012] (Section [IP_ADDRESS] ). Although traditional RECIST 1.[ADDRESS_977338] 1.1 to allow a maximum of 10 target lesions in total and 5 per 
organ.
[IP_ADDRESS].[ADDRESS_977339] for Immune -based Therapeutics (iRECIST)
RECIST 1.1 will be adapted to account for the unique tumor response characteristics seen 
following treatment with pembrolizumab (Section 8.2.1. 5). Immunotherapeutic agents such 
as pembrolizumab may produce antitumor effects by [CONTACT_306156]-specific 
immune responses. The response patterns seen with such an approach may extend beyond the 
typi[INVESTIGATOR_264788], and patients treated with 
pembrolizumab may manifest a clinical response after an initial increase in tumor burden or 
even t he appearance of new lesions. Thus, standard RECIST 1.1 may not provide an accurate 
response assessment of immunotherapeutic agents such as pembrolizumab. Based on an 
analysis of participants with melanoma enrolled in KEYNOTE -001 (KN001), 7% of 
evaluable p articipants experienced delayed or early tumor pseudo- progression. Of note, 
participants who had progressive disease (PD) by [CONTACT_393] 1.1 but not by [CONTACT_246750] -related 
response criteria [Wolchok, J. D., et al 2009] had longer overall survival than participants 
with PD by [CONTACT_119580] [Hodi, F. S., et al 2014] . Additionally, the data suggest that RECIST 
1.1 may underestimate the benefit of pembrolizumab in approximately 15% of participants. 
These findings support the need to apply a modification to RECIST 1.[ADDRESS_977340] 1.1 for immune -based therapeutics (iRECIST) assessment has been 
developed and published by [CONTACT_264818], with input from leading experts 
from industry and academia, along with participation from the US Food and Drug 
Administration and the European Medicines Agency [Seymour, L., et al 2017] . The 
unidimensional measurement of target lesions , qualitative assessment of non target lesions, 
and response categories are id entical to RECIST 1.1, until progression is seen by [CONTACT_393] 
1.1. However, if a participant is clinically stable, additional imaging may be performed to 
confirm radiographic progression. iRECIST will be used by [CONTACT_717013] .
06FWC3
0833R8
0833R8
PRODUCT: MK 3475 SCH 900475 47
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS] Planned Exploratory Biomarker Research
Cancer immunotherapi[INVESTIGATOR_19325]. 
However, the mechanism of action of these exciting new therapi[INVESTIGATOR_306130]. Thus, to aid future patients, it is important to investigate the determinants 
of response or resistance to cancer im munotherapy and other treatments administered, as well 
as determinants of AEs in the course of our clinical studies. These efforts may identify novel 
predictive/PD biomarkers and generate information that may better guide single -agent and 
combination thera py with immuno -oncology drugs. To identify novel biomarkers, 
biospecimens (ie, blood components, tumor material) will be collected to support analyses of 
cellular components (eg, protein, DNA, RNA, metabolites) and other circulating molecules. 
Investigations may include but are not limited to:
Germline (blood) genetic analyses (eg, SNP analyses, whole exome sequencing, whole 
genome sequencing)
This research may evaluate whether genetic variation within a clinical study population 
correlates with response to the treatment(s) under evaluation. If genetic variation is found to 
predict efficacy or AEs, the data might inform optimal use of therapi[INVESTIGATOR_113742]. Furthermore, it is important to evaluate germline DNA variation across the 
genome in ord er to interpret tumor -specific DNA mutations. In addition to studying 
variation across the human genome, cfDNA -based technologies enable blood -based 
interrogation of tumor genetics, including total TMB, tumor immune -editing, and tumor 
evolution.  cfDNA analysis represents a more complete snapshot of total tumor genetics of 
primary and metastatic lesions over single -site,biopsy- based analyses. cfDNA technologies 
allows interrogation of tumor genetics without the risk of invasive biopsies and being a blood 
marker enables routine tumor genetics assessment over the course of therapy .Finally, 
microsatellite instability (MSI ) may be evaluated as this is an important biomarker for some 
cancers (ie, colorectal cancer).
Genetic (DNA) analyses from tumor
The application of new technologies, such as next generation sequencing, has provided 
scientists the opportunity to identify tu mor-specific DNA changes (ie, mutations, methylation 
status, microsatellite instability). Key molecular changes of interest to immuno -oncology 
drug development include the mutational burden of tumors and the clonality of T -cells in the 
tumor microenvironme nt. Increased mutational burden (sometimes referred to as a ‘hyper -
mutated’ state) may generate neo -antigen presentation in the tumor microenvironment. To 
conduct this type of research, it is important to identify tumor -specific mutations that occur 
across all genes in the tumor genome. Thus, genome -wide approaches may be used for this 
effort. Note that in order to understand tumor -specific mutations, it is necessary to compare 
the tumor genome with the germline genome. Microsatellite instability may also b e evaluated 
as this is an important biomarker for some cancers (ie, colorectal cancer). Circulating tumor 
DNA and/or RNA may also be evaluated from blood samples.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 48
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Tumor and blood RNA analyses
Both genome -wide and targeted messenger RNA (mRNA) expression profiling and 
sequencing in tumor tissue and in blood may be performed to define gene signatures that 
correlate to clinical response to treatment with pembrolizumab or other immunotherapi[INVESTIGATOR_014]. 
Pembrolizumab induce sa response in tumors that likely reflects an inflamed/immune 
phenotype. Specific immune -related gene sets (ie, those capturing interferon- gamma 
transcriptional pathways) may be evaluated and new signatures may be identified. Individual 
genes related to the immune system may also be evaluated (eg, IL -10). MicroRNA profiling 
may also be pursued as well as exosomal profiling.
Proteomics and immunohistochemistry (IHC) using blood or tumor
Tumor and blood samples from this study may undergo proteomic analyses (eg, PD -L1 IHC). 
PD-L1 protein level in tumor sections, assessed by [CONTACT_4658], has been shown to correlate with 
response to pembrolizumab in patients with NSCLC, and an in vitro diagnostic (IVD) device 
has been developed for use with pembrolizum ab in NSCLC. Preliminary data indicates that 
this association may also be true in additional cancer types (ie, triple negative breast cancer, 
head and neck, and gastric). Additional tumor or blood -derived proteins may also correlate 
with response to pembro lizumab . Therefore, tumor tissue may be subjected to proteomic 
analyses using a variety of platforms that could include but are not limited to immunoassays 
and liquid chromatography/mass spectrometry. This approach could identify novel protein 
biomarkers t hat could aid in patient selection for pembrolizumab (MK -3475) therapy.
Other blood
-derived biomarkers
In addition to expression on the tumor tissue, PD -L1 and other tumor derived proteins can be 
shed from tumor and released into the blood. Assays such as enzyme -linked immunoassay 
(ELISA) measure such proteins in serum . Correlation of expression with response to 
pembrolizumab therapy may identify new approaches for predictive biomarkers in blood, 
representing a major advance from today’s reliance on assessing tumor biomarkers. This 
research would serve to develop such assays for future clinical use.
Other molecular changes of interest include the subtype of T -cells in the tumor 
microenvironment. The T -cell repertoire from tumor tissue and blood components ma y be 
evaluated.
Microbiome analysis of stool
Stool samples from this study will be collected to assess the microbiome ass ociated with 
clinical activity. This research may help identify factors predictive of pembrolizumab 
response and resistance and novel targets for cancer immunotherapy.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 49
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Metabolomics
Blood samples from this study will be collected to assess the metabolomics profiles 
associated with clinical activity. This research may help identify factors predictive of 
pembrolizumab response and resistance and novel targets for cancer immunotherapy.
[IP_ADDRESS].[ADDRESS_977341] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic de terminants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a sample will b e collected for DNA analysis 
from consenting participants.
DNA samples may be used for research related to the study intervention( s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests rel ated to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes , the analysis of genetic 
markers throughout the genome , or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to understand study disease or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study. This research may include genetic analyses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabo lomics (serum, plasma), 
and/or the measurement of other analytes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as pa rt of the main study) and will only be conducted on specimens from 
appropriately consented participants. The objective of coll ecting/retaining specimens for 
future biomedical r esearch is to explore and identify biomarkers that inform the scientific 
underst anding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy are presented in Appendix 6.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 50
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
4.3 Justification for Dose
Pembrolizumab
Pembrolizumab 200 mg IV Q3W is the approved dose for the NSCLC indication per the 
current label .
Chemotherapy
This study will use SOC dosing for carboplatin at AUC 5 mg•min/mL ≤50mg, cisplatin at 
75mg/m2, and pemetrexed at 500 mg/m2in participants with NSCLC. Refer to the 
carboplatin, cisplatin, and pemetrexed prescribing information for more information.
4.[ADDRESS_977342] to follow -up (ie, the participant is unable to be contact[CONTACT_24992]).
Upon study completion, participants are discontinued and may be enrolled in a 
pembrolizumab extension study, if available.
Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study early.
5 STUDY POPULATION
Male/ female participants with metastatic NSCLC who have received no systemic anticancer 
therapy for their metastatic NSCLC and who are at least [ADDRESS_977343] :
1.Have a histologically- confirmed or cytologically confirmed diagnosis of stage IV (M1a ,
M1b, or M1c [ AJCC 8thedition] ) nonsquamous NSCLC.
2.Have confirmation that epi[INVESTIGATOR_3506] (EGFR -), anaplastic 
lymphoma kinase (ALK -), c-ros oncogene 1 (ROS1), or B isoform of rapi[INVESTIGATOR_716988] ( BRAF ) directed therapy is not indicated as primary therapy. 
Documentation of the absence of tumor activating EGFR mutations, B RAF mutations, 
ALKgene rearrangements, and ROS1 gene rearrangem entsis required. 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 51
PROTOCOL/AMENDMENT NO.: [ADDRESS_977344] 1.1 as determined by [CONTACT_219526]/radiology assessment.  Target lesions s ituated in a previously irradiated area 
are considered measurable if progression has been demonstrated in such lesions.
4.Have not received prior systemic treatment for their advanced/metastatic NSCLC. 
Participant s who received adjuvant or neoadjuvant therap y are eligible if the 
adjuvant /neoadjuvant therapy was completed at least [ADDRESS_977345] provided sufficient evaluable Stage IV, archival, solid tumor tissue sample or newly 
obtained core or excisional biopsy of a tumor lesion (that was not previously irradiated) 
for biomarker analysis (Fine Needle A spi[INVESTIGATOR_1516] [FNA] samples will not be accepted).
Formalin- fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly 
obtained biopsies are preferre d to archived tissue. (See Procedures Manual for specific 
details.)
Demographics
6.Participant is ≥18years of age inclusive, at the time of signing the informed consent.
7.Have an ECOG performance status of [ADDRESS_977346] 120 days, corresponding to time needed to eliminate any 
study intervention(s) ( pembrolizumab and/or any active comparator/combination) plus an 
additional 90 days (a spermatogenesis cycle) for study interventions where there is risk of 
clinically relevant genotoxicity after the last dose of study intervention and refrain from 
donating sperm during this period.
Female Participants
9.Not be pre gnant (Appendix 5) or breastfeeding, and at least 1 of th e following conditions 
applies:
a)Not be a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b)A WOCBP must agree to follow the contraceptive guidance in Appendix [ADDRESS_977347] 120days (corresponding to time needed to 
eliminate any study intervention(s) ( pembrolizumab and or any active 
comparator/combination) after the last dose of pembrolizumab .
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 52
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Informed Consent
13.The participant (or legally acceptab le representative if applicable) provides written 
informed consent/assent for the study. The participant may a lso provide consent/assent 
for future biomedical r esearch. However, the participant may participate in the main 
study without participating in future biomedical r esearch.
Laboratory Values
14.Have adequate organ function as indicated by [CONTACT_218593] 2. 
Specimens must be collected and reviewed within 10 days prior to the start of study 
treatment.
Table 2 Adequate Organ Function Laboratory Values
System Laboratory Value
Hematologic
Absolute neutrophil count (ANC) ≥1500/ µL
Platelets ≥100 000/µL
Hemoglobin ≥9 g/dL or ≥5.6 mmol/La
Renal
Creatinine OR
Measured or c alculated CrClb
(GFR can also be used in place of creatinine or CrCl)≤1.5 × ULN OR
≥30mL/min forparticipants with creatinine levels 
>1.5 × institutional ULN
Hepatic
Total bilirubin (serum) ≤1.5 ×ULN ORdirect bilirubin ≤ULN for 
participants with total bilirubin levels >1.5 ×ULN .
If there is no institutional ULN, then direct bilirubin 
must be <40% of total bilirubin to be eligible. Note: 
In no case can the total bilirubin exceed [ADDRESS_977348] (SGOT) and ALT (SGPT) ≤2.5 × ULN or ≤5 × ULN for participants with liver 
metastases
Coagulation
International normalized ratio or prothrombin time 
(PT)
Activated p artial thromboplastin time (aPTT) or 
partial thromboplastin time (PTT)c≤1.5 ×ULN unless the participant is receiving 
anticoagulant therapy as long as PT or PTT is within 
therapeutic range of intended use of anticoagulants
Note: This table includes eligibility defining laboratory value requirements for treatment; laboratory value requirements 
should be adapted according to local regulations and guidelines for the administration of specific chemotherapi[INVESTIGATOR_014] .
aCriteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 
2weeks of the screening test. Participants can be on stable dose of erythropoietin (≥ approximately 3 months).
bCrCl should be calculated per institutional standard.
cPTT may be performed if the local lab is unable to perform aPTT.
Abbreviations: ALT (SGPT) alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)
aspartate aminotransferase (serum glutamic oxaloacetic transaminase); CrCl creatini ne clearance; GFR glomerular 
filtration rate; ULN upper limit of normal.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 53
PROTOCOL/AMENDMENT NO.: [ADDRESS_977349] be excluded from the study if the participant:
Medical Co nditions
1.Has predominantly squamous cell histology NSCLC. Mixed tumors will be categorized 
by [CONTACT_19400] .
2.Has small cell elements pre sentin NSCLC tumor .
3.Is aWOCBP who has a positive urine pregnancy test within 72 hours prior to treatment 
(see Appendix 5). If the urine test is positive or cannot be confirmed as negative, a serum 
pregnancy test will be required.
Note:  In the event that [ADDRESS_977350] (urine or serum) must be 
performed and must be negative in order for participant to start receiving study 
medication.
4.Hasclinically active diverticulitis, intra -abdomi nal abscess, GI obstruction, peritoneal
carcinomatosis .
5.Has a known histo ry of prior malignancy except if the participant has undergone 
potentially curative therapy with no evidence of that disease recurrence for 2years since 
initiation of that therapy.  
Note: The time requirement for no evidence of disease for 2years does not apply to the 
NSCLC tumor for which a participant is enrolled in the study.  The time requirement also 
does not apply to participant s who underwent successful definitive resection of basal cell 
carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in 
situ cervical cancer, or other in situ cancers .
6.Has symptomatic ascites or pleural effusion. A participant who is clinically stable 
following treatment f or these conditions (including therapeutic thoraco- or paracentesis) 
is eligible.
Prior/Concomitant Therapy
7.If participant received major surgery, they must have recovered adequately from the 
toxicity and/or complications from the intervention prior to sta rting study intervention.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 54
PROTOCOL/AMENDMENT NO.: [ADDRESS_977351] had radiation pneumonitis. A 1 -week w ashout is permitted for palliative 
radiation ( ≤2 weeks of radiotherapy) to non- central nervous system ( CNS )disease.
9.Has received prior therapy with a PD -1/PD -L1 receptor inhibitor.
10.Is expected to require any other form of antineoplastic therapy w hile on s tudy (including 
maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical 
resection) .
11.Has received a live vaccine within 30 days prior to treatment . Examples of live vaccines 
include, but are not limited to, the following: measle s, mumps, rubella, varicella/zoster 
(chicken pox), yellow fever, rabies, Bacillus Calmette Guérin (BCG), and typhoid 
vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and 
are allowed; however, intranasal influenza vaccines (e .g., FluMist®) are live attenuated 
vaccines and are not allowed.
12.Has severe hypersensitivity ( ≥Grade 3) to pembrolizumab and/or any of its excipi[INVESTIGATOR_716989].
13.Has a known sensitivity to any component of cisplatin, carboplatin or pemetrexed.
14.Has active autoimmune disease that has required systemic treatment in past 2 years (ie ,
with use of disease -modifying agents, corticosteroids, or immunosuppressive drugs).  
Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement 
therapy for adrenal or pi[INVESTIGATOR_13002]) is not considered a form of systemic 
treatment.
15.Is on chronic systemic steroids. Participa nts with asthma that require intermittent use of 
bronchodilators, inhaled steroids, or local steroid injections would not be excluded from 
the study. 
16.Is unable or unwilling to take folic acid or vitamin B 12supplementation.
Prior/Concurrent Clinical Study Experience
17.Is currently participating in or has participated in a study of an investigational agent or 
has used an investigational device within [ADDRESS_977352] dose of study 
intervention.
Note: Participants who have entered the follow -up phase of an investigational study may 
participate as long as it has been [ADDRESS_977353] dose of the previous 
investigational agent.
Note: Participants must have recovered from all AEs due to previous therapi[INVESTIGATOR_24305] 
≤Grade 1 or baseline. Participants with ≤Grade [ADDRESS_977354]: MK 3475 SCH 900475 55
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Diagnostic Assessments
18.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in 
dosing exceeding 10 mg daily of prednisone equivalent) or any other form of 
immunosuppressive therapy withi n [ADDRESS_977355] 2years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the 
skin,or ca rcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have 
undergone potentially curative therapy are not excluded.
20.Has known active CNS metastases and/or carcinomatous meningitis. Participants with 
previously treated brain metastases may pa rticipate provided they are radiologically 
stable, (ie, without evidence of progression) for at least 4 weeks by [CONTACT_19406] (note 
that the repeat imaging should be performed during study screening), clinically stable and 
without requirement of steroid treatment for at least [ADDRESS_977356] dose of study 
intervention.
21.Has a history of (non -infectious) pneumonitis that required steroids or has current 
pneumonitis.
22.Has an active infection requiring systemic therapy.
23. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing 
is required unless mandated by [CONTACT_14306].
24.Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] 
reactive) or  known active Hepatitis C virus (defined as HCV RNA [q ualitative] is 
detected) infection.
Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by [CONTACT_19384].
25.Has a history or current evidence of any condition, therapy, or laboratory abnormality 
that might confound the results of the study, interfere with the participant's participation 
for the full duration of the study, or is not in the best interest of the participant to 
participate, in the opi[INVESTIGATOR_80021].
26.Has a known psychiatric or substance abu se disorder that would interfere with the 
participant’s ability to cooperate with the requirements of the study.
Other Exclusions
27.Is pregnant or breastfeeding or expecting to conceive or father children within the 
projected duration of the study, starting with the screening visit through [ADDRESS_977357] dose of study intervention.
28.Has had an allogenic tissue/solid organ transplant.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 56
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
5.3 Lifestyle Considerations
Meals and Dietary Restrictions
Participants should maintain a normal diet unless modifications are required to manage an 
AE such as diarrhea, nausea, or vomiting.
Caffeine, Alcohol ,and Tobacco Restrictions
During each dosing session, participants will abstain from alcohol from24 hours before the 
start of dosing until after collection of the metabolomic sample. Ethanol and its metabolites 
are also products of bacterial metabolism and alcohol use may interfere with the translational 
metabolomics analyses.
Activity Restrictions
Participants will abstain from strenuous exercise (eg, swimm ing, running, or any gym 
workout )for 4 hours before each blood collection for cfDNA and metabolomics analysis .
Participant may resume normal activity following blood draw , as per i nvestigator ’s 
instructions. Participants should wait to have all blood samples collected at the visits before 
exercise.  Participants may participate in light recreational activities during studies (e g, 
watching television, reading).
Contraception
Pembrolizumab may have adverse effects on a fetus in utero. Refer to App endix 5 for 
approved methods of contraception.
Participants should be informed that taking the study medication may involve unknown risks 
to the fetus (unborn baby) if pregnancy were to occur during the study . In order to participate 
in the study, particip ants of childbearing potential must adhere to the contraception 
requirement ( Appendix 5 ) from the day of study medication initiation (or 14 days prior to the 
initiation of study medication for oral contraception) throughout the study period up to 
120days after the last dose of study medication. If there is any question that a participant of 
childbearing potential will not reliably comply with the requirements for contraception, that 
participant should not be entered into the study.
Pregnancy
If a participa nt inadvertently becomes pregnant while on treatment with pembrolizumab, the 
participant will be immediately d iscontinued from study intervention. The site will contact 
[CONTACT_717014]’s status until the pregna ncy has 
been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor 
without delay and within 24 hours if the outcome is a serious adverse experience (eg, death, 
abortion, congenital anomaly, or other disabling or life -threatening complication to the 
mother or newborn). The study Investigator will make every effort to obtain permission to 
follow the outcome of the pregnancy and report the condition of the fetus or newborn to the 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 57
PROTOCOL/AMENDMENT NO.: [ADDRESS_977358] be reported to the Sponsor and 
followed as described in Section 8.4.1.
Use in Nursing Women
It is unknown whether pembrolizumab is excreted in human milk. Sin ce many drugs are 
excreted in human milk, and because of the potential for serious adverse reactions in the 
nursing infant, participants who are breastfeeding are not eligible for enrollment.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently entered in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Report ing Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who discontinues from study intervention OR withdraws from the study will 
not be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol.
Centrally sourced Cl inical supplies (study interventions provided by [CONTACT_1034] )will be 
packaged to support enrollment .  These Clinical supplies will be affixed with a clinical label 
in accordance with regulatory requirements.
Locally sourced clinical supplies will be provided locally by [CONTACT_717015] 6.1.
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study areoutlined inTable [ADDRESS_977359]: MK 3475 SCH 900475 58
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Table 3 Study Intervention s
Arm 
NameArm 
TypeIntervention 
NameTypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegimen/Treatment 
Period/Vaccination 
RegimenUseIMP/
NIMPSourcing
NAOther pembrolizumab
(MK -3475)Biological/
VaccineSolution for 
Infusion25 mg / mL 200 mg IV 
InfusionDay 1 of each 21 -day 
cycleSOC IMP Central 
NAOtherpemetrexedDrug Lyophilized 
Powder500 mg 500 
mg/m 2IV 
InfusionDay 1 of each 21 -day 
cycleSOC NIMP US: 
Local
ex-US: 
Central 
NAOther carboplatin Drug Solution for 
Infusion10 mg / mL AUC 5 
mg/mL/
minIV 
InfusionDay 1 of each 21 -day 
cycle for 4 cycles  
(Cycles 1 –4)SOC NIMP US: 
Local
ex-US: 
Central 
NAOther cisplatin Drug Solution for 
Infusion1 mg/ mL 75
mg/m2IV 
InfusionDay 1 of each 21 -day 
cycle for 4 cycles 
(Cycles 1 –4)SOC NIMP US: 
Local
ex-US: 
Central 
Definition Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) arebased on guidance issued by [CONTACT_180620]. Regional and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, local legisl ation is followed. SOC = 
Standard of care.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 59
PROTOCOL/AMENDMENT NO.: [ADDRESS_977360] include pemetrexed plus the i nvestigator’s choice of either 
cisplatin or carboplatin.  Upon IVRS allocation, the investigator will assign each participant 
to either cisplatin or carboplatin, as determined by [CONTACT_093].
Allstudy interventions will be administered on an outpatient basis.
All products indicated in Table [ADDRESS_977361] that is provided by [CONTACT_3452], subsidiary, or 
designee, every attempt will be made to source these supplies from a s ingle lot/batch number. 
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_113743].
Refer to Section 8.1.8 for details regar ding administration of the study intervention.
6.2 Preparation/Handling/Storage/Accountability
Dose Preparation
Details on preparation and administration of pembrolizumab are provided in the Pharmacy 
Manual. Concomitant chemotherapeutic/immunotherapeutic agen ts will be prepared and 
administered as per the approved product label(s ).
Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and any discrepancies are 
reported and resolved before use of the study intervention .
Only participants enrolled in the study may receive study intervention, and only authorized 
site staff may supply or administer study intervention. All study i nterventions must be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sp onsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 60
PROTOCOL/AMENDMENT NO.: [ADDRESS_977362] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protoc ol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
Intervention Assignment
Participants in this study will be allocated by [CONTACT_148195].
Stratification
No stratification based on age, sex, or other ch aracteristics will be used in this study.
Blinding
This is an open -label study ; therefore, the Sponsor, investigator, and participant will know 
the interventions administered.
6.4 Study Intervention Compliance
Administration of study medicati on(s) will be witnessed by [CONTACT_941] i nvestigator and/or study 
staff. The total volume of study medication infused will be compared with the total volume 
prepared to determine compliance with each dose administered.
Interruptions from the protocol -specified treatment plan for ≥21days require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on participant management.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing study. If there is a clinical indication for any medication or vaccination 
specifically prohibited, discontinuation from study therapy or vaccination may be required. 
The investigator should discuss any questions regarding this with the Sponsor's Clinical 
Director. The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the participant's primary physician. However, the decision to continue the 
participant on study intervention requires t he mutual agreement of the investigator, the 
Sponsor, and the participant.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 61
PROTOCOL/AMENDMENT NO.: [ADDRESS_977363] of specifically prohibited medications or devices for this study:
•Antineoplastic systemic chemotherapy or biological therapy not specified in this protocol
Note: den osumab is permitted .
•Immunotherapy not specified in this protocol
•Chemotherapy not specified in this protocol
•Investigational agents other than pembrolizumab
•Radiation therapy
Note: Radiation therapy to a symptomatic solitary lesion or to t he brain may be allowed 
at the i nvestigator’s discretion, provided the lesions were not previously defined by [CONTACT_717016] .
•Live vaccines within [ADDRESS_977364] dose of study intervention and while 
participating in the study
Examples of live vacci nes include, but are not limited to, the following: measles, mumps, 
rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal 
influenza vaccines for injection are generally killed virus vaccines and are allowed; 
however, intranasa l influenza vaccines (eg, FluMist®) are live attenuated vaccines and 
are not allowed.
•Prolonged therapy with systemic glucocorticoids (>7days) foranypurpose other than to
modulate symptoms from anAE,SAE, orECIorforuseasapremedication for
chemotherapy orinparticipants with aknown history ofanIVcontrast allergy
administered aspartofCT radiography. Brief, limited useofsystemic corticosteroids (≤7
days) arepermitted where such useisconsidered SOC (eg,forCOPD exacerbation).
•Replacement doses ofsteroids (eg,prednisone 5to7.5mgdaily) arepermitted while on
study, asistheuseoflocal steroids .
Participants who, in the assessment of the Investigator, require the use of any of the 
aforementioned treatments for clinical management should be removed from the study.
All treatments that the i nvestigator considers necessary for a participant’s welfare may be 
administered at the discretion of the i nvestigator in keepi[INVESTIGATOR_12983]. All concomitant medication will be recorded on the eCRF including all 
prescription, over -the-counter (OTC) products, herbal supplements, and IV medications and 
fluids. If changes occur during the study period, documentation of d rug dosage, frequency, 
route, and date should also be included on the eCRF.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 62
PROTOCOL/AMENDMENT NO.: [ADDRESS_977365] (ECIs) as defined in Section 
8.4.7.
Probiotics and Prebiotics
Use of c ommercially available prebiotics and probiotic supplements will be monitored on 
study. Any prebiotic or probiotic use should be recorded in the concomitant medications 
eCRF . Examples of r epresentative prebiotic and probiotics are listed below. The list is not 
comprehensive.  
•Probiotics may include products containing any of the following:
•Bifidobacterium spp .
•Saccharomyces boulardii
•Lactobacillus spp.
Prebiotics are dissacharide containing supplements including lactulose ;oligosaccharides ,
including fructo -oligosaccharides (FOS), galacto -oligosaccharides (GOS), isomalto-
oligosaccharides, xylo -oligosaccharides, transgalacto -oligosaccharides (TGOS) ,and soybean 
oligosaccharides ;and polysaccharides, such as the fructan inulin, reflux starch, cellulose, 
hemicellulose or pectin .
Rescue Medications and Supportive Care
Participants should receive appropriate supportive care measures as deemed necessary by [CONTACT_78017]. Suggested supportive care measures for the management of AEs with 
potential immunologic etiology are outlined along with the dose modification guidelines in 
Section 6.6, Table 4 .Where appropriate, these guidelines include the use of oral or IV 
treatment with corticosteroids, as well as additional anti -inflammatory agents if symptoms do 
not improve with administration of corticosteroids. Note that several courses of steroid 
tapering may be necessary as symptoms may worsen when the s teroid dose is decreased. For 
each disorder, attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care. The treatment 
guidelines are i ntended to be applied wh en the i nvestigator determines the events to be 
related to pembrolizumab.
Note: If after the evaluation of the event, it is determined not to be related to pembrolizumab, 
the investigator does not need to follow the treatment guidance. Refer to   in Section 6.6for 
guidelines regarding dose modification and supportive care.
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or 
skin photography as part of evaluation of the event.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 63
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
6.6 Dose Modification (Escalation/Titration/Othe r)
If appropriate, the i nvestigator may attribute each toxicity event to cisplatin/carboplatin, 
pemetrexed, or pembrolizumab alone or to the combination and use a stepwise dose 
modification according to Table [ADDRESS_977366] be based on the 
maximum toxicity experienced during a cycle. Toxicity needs to resolve to Grade ≤1 or 
baseline prior to resuming subsequent cycle. For individual participants requiring a dose 
modification, treatment for each new cycle may be delayed if the scheduled off -drug periods 
are not adequate to allow for recovery to Grade ≤[ADDRESS_977367] a maximum of 2 dose 
modifications (if applicable) to each of the components of study therapy throughout the 
course of the study for toxicities.  If a participant experiences several toxicities and there are 
conflicting recommendat ions, the most conservative dose adjustment recommended should 
be followed (dose reduction appropriate to the most severe toxicity). Participants who require 
a third dose modification to any particular component will have that agent discontinued.
Reduction of one chemotherapy agent and not the other agent is appropriate if, in the opi[INVESTIGATOR_41657] i nvestigator, the toxicity is clearly related to one of the treatments. If, in the opi[INVESTIGATOR_13046], the toxicity is related to th e combination of both chemotherapy agents, both 
drugs should be reduced according to recommended dose modifications. If the toxicity is 
related to the combination of 3agents, all 3 agents should be reduced (if applicable), 
interrupted, or discontinued acc ording to the recommended dose modifications. Participants
may have chemotherapy discontinued and continue on pembrolizumab alone.  Similarly ,
participants may discontinue pembrolizumab and continue on chemotherapy alone ,if 
appropriate ,through the durati on of study participation (ie, up to 35 total cycles ).
Chemotherapy may be interrupted for a maximum of [ADDRESS_977368] dose; pembrolizumab 
may be interrupted for a maximum of [ADDRESS_977369] dose.
The Common Terminology Criteria for Adverse Events ve rsion 4.0 (CTCAE 4.0) must be 
used to grade the severity of adverse events. All dose modifications should be based on the 
AE requiring the greatest dose modification. Dose m odifications are detailed in Table [ADDRESS_977370]: MK 3475 SCH 900475 64
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Table 4 Dose Modifications for Trial Medications
Dose Level 0 Dose Level -1 Dose Level -2 Dose Level -3
Cisplatin 75 mg/m256 mg/m238 mg/m2Discontinue
CarboplatinAUC 5
Maximum dose 
750mgAUC 3.75
Maximum dose 
562.5 mgAUC 2.5
Maximum dose 
375mgDiscontinue
Pemetrexed 500mg/m2 375 mg/m2250 mg/m2Discontinue
Pembrolizumab 200 mg fixed doseDose reductions 
are not permitted .Dose reductions 
are not permitted .Dose reductions 
are not permitted
Dose Modification
Dose Modification and Toxicity Management for Immune-r elated AEs Associated with 
Pembrolizumab
AEs associated with pembrolizumab exposure may represent an immunologic etiology. 
These immune -related AEs (irAEs) may occur shortly after the first dose or several months 
after the last dose of pembrolizumab treatment and may affect more tha n onebody system 
simultaneously. Therefore, early recognition and initiation of treatment is critical to reduce 
complications. Based on existing clinical study data, most irAEs were reversible and could 
be managed with interruptions of pembrolizumab, administr ation of corticosteroids and/or 
other supportive care. For suspected irAEs, ensure adequate evaluation to confirm etiology or 
exclude other causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin 
biopsy may be included as part of the e valuation. Based on the severity of irAEs, withhold or 
permanently discontinue pembrolizumab and administer corticosteroids. Dose modification 
and toxicity management guidelines for irAEs associated with pembrolizumab are provided 
inTable [ADDRESS_977371]: MK 3475 SCH 900475 65
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Table 5 Dose Modification and Toxicity Management Guidelines for Immune -related AEs Associated with Pembrolizumab
General instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_977372] dose or corticosteroids cannot be reduced to 
≤[ADDRESS_977373] followed by [CONTACT_44874]. Other immunosuppressive treatment sh ould be 
initiated if irAEs cannot be controlled by [CONTACT_13216].
Immune- related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with corticosteroid 
and/or other therapi[INVESTIGATOR_47418]- up 
Pneumonitis Grade 2 Withhold •Administer corticosteroids (initial dose 
of 1-2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]•Monitor participants for signs and 
symptom s of pneumonitis
•Evaluate participants with suspected 
pneumonitis with radiographic imaging 
and initiate corticosteroid treatment
•Add prophylactic antibiotics for 
opportunistic infectionsGrade 3 or 4, or 
recurrent Grade 2Permanently 
discontinue
Diarrhea / Colitis Grade 2 or 3 Withhold•Administer corticosteroids (initial dose 
of 1-2 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]•Monitor participants for signs and 
symptoms of enterocolitis (ie, diarrhea, 
abdominal pain, blood or mucus in stool 
with or without fever) and of bowel 
perforation (ie, peritoneal signs and ileus)
•Participants with ≥Grade 2 diarrhea 
suspecting colitis should consider GI 
consultation and performing endoscopy to 
rule out colitis
•Participants with diarrhea/colitis should 
be advised to drink liberal quantities of 
clear fluids. If sufficient oral fluid intake 
is not feasible, fluid and electrolytes 
should be substituted via IV infusion.Grade [ADDRESS_977374]: MK 3475 SCH 900475 66
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Immune- related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with corticosteroid 
and/or other therapi[INVESTIGATOR_47418]- up 
AST / ALT 
elevation or 
Increased 
BilirubinGrade 2 Withhold•Administer corticosteroids (initial dose 
of 0.5 -1 mg/kg prednisone or 
equivalent) followed by [CONTACT_13217]•Monitor with liver function tests 
(consider weekly or more frequently until 
liver enzyme value returned to baseline or
is stable) Grade 3 or 4 Permanently 
discontinue•Administer corticosteroids (initial dose 
of 1-2 mg/kg prednisone or 
equivalent) followed by [CONTACT_133390] 1 diabetes 
mellitus (T1DM) 
or 
HyperglycemiaNew onset T1DM or 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of -cell 
failureWithhold•Initiate insulin replacement therapy for 
participants with T1DM
•Administer anti -hyperglycemic in 
participants with hyperglycemia•Monitor participants for hyper glycemia or 
other signs and symptoms of diabetes
Hypophysitis Grade 2 Withhold•Administer corticosteroids and initiate 
hormonal replacements as clinically 
indicated•Monitor for signs and symptoms of 
hypophysitis (including hypopi[INVESTIGATOR_178870])Grade 3 or 4 Withhold or 
permanently 
discontinue1
Hyperthyroidism Grade 2 Continue•Treat with non -selective beta- blockers 
(eg, propranolol) or thionamides as 
appropriate•Monitor for signs and symptoms of 
thyroid disorders
Grade 3 or 4 Withhold or 
Permanently 
discontinue1
Hypothyroidism Grade 2 -4 Continue•Initiate thyroid replacement hormones 
(eg, levothyroxine or liothyronine) per 
standard of care•Monitor for signs and symptoms of 
thyroid disorders
Nephritis and 
renal dysfunctionGrade 2 Withhold•Administer corticosteroids (prednisone 
1-2 mg/kg or equivalent) followed by 
[CONTACT_13217]•Monitor changes of renal function
Grade [ADDRESS_977375]: MK 3475 SCH 900475 67
PROTOCOL/AMENDMENT NO.: [ZIP_CODE]
MK 3475 78202FINAL PROTOCOL 20AUG 2021
Immune- related 
AEsToxicity grade or 
conditions 
(CTCAEv4.0)Action taken to 
pembrolizumabirAE management with corticosteroid 
and/or other therapi[INVESTIGATOR_47418]- up 
Myocarditis Grade 1 or 2 Withhold•Based on severity of AE administer 
corticosteroids•Ensure adequate evaluation to confirm 
etiology and/or exclude other causes
Grade 3 or 4 Permanently 
discontinue
All Other 
immune -related 
AEsIntolerable/persistent 
Grade 2Withhold•Based on severity of AE administer 
corticosteroids•Ensure adequate evaluation to confirm 
etiology or exclude other causes
Grade 3 Withhold or 
discontinue based 
on the type of event. 
Events that require 
discontinuation 
include and not 
limited to: Guillain -
Barre Syndrome, 
encepha litis
Grade 4 or recurrent 
Grade 3Permanently 
discontinue
1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.
NOTE:
For participants with Grade 3 or 4 immune -related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be resumed when AE 
resolves to ≤ Grade 2 and is controlled with hormonal replacement therapy or achieved metabolic control (in case of T1DM).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 68
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Dose Modification and Toxicity Management of Infusion Reactions Related to 
Pembrolizumab
Pembrolizumab may cause severe or life-threatening infusion- reactions including severe 
hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of completion of infusion. 
Dose modification and toxicity management guidelines on pembrolizumab associated 
infusion reaction are provided inTable 6 .
Table 6 Pembrolizumab Infusion Reaction D ose Modification and Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until t he participant is 
deemed medically stable in the opi[INVESTIGATOR_296421] 2
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e g, antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrsStop Infusion
Additional appropriate medical therapy may 
include but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the participan t is 
deemed medically stable in the opi[INVESTIGATOR_1070].
If symptoms resolve within 1 hour of 
stoppi[INVESTIGATOR_13056], the infusion may be 
restarted at 50% of the original infusion rate 
(eg, from 100 mL/hr to 50 mL/hr). Otherwise 
dosing will be held until symptoms resolve 
and the participant should be premedicated 
for the next scheduled dose.
Participants who develop Grade 2 toxicity 
despi[INVESTIGATOR_716990] f rom further study 
drug intervention.Participant ma y be 
premedicated 1.5 h (±30 
minutes) prior to infusion 
of pembrolizumab with:
Diphenhydramine 50 mg 
PO(or equivalent dose of 
antihistamine).
Acetaminophen 500 -1000 
mg PO(or equivalent dose 
of analgesic).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 69
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
NCI CTCAE Grade TreatmentPremedication at 
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (ie, not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_12258] (eg, 
renal impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
Epi[INVESTIGATOR_238]**
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increa se monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_1070].
Hospi[INVESTIGATOR_13021].
**In cases of anaphylaxis, epi[INVESTIGATOR_90943].
Participant is per manently discontinued from 
further study drug intervention.No subsequent dosing
Appropriate resuscitation equipment should be available at the bedside and a physician readily available 
during the period of drug administration.
For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 
at http://ctep.cancer.gov
Other Allowed Dose Interruption for Pembrolizumab
Pembrolizumab may be interrupted for situations other than treatment -related AEs such as 
medical / surgical events or logistical reasons not related to study therapy. Participants should 
be placed back on study therapy within 3 weeks of the scheduled interruption, unless 
otherwise discussed with the Sponsor. The reason for interruption should be documented in 
the pa rticipant 's study record.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 70
PROTOCOL/AMENDMENT NO.: [ADDRESS_977376] investigator judgment and applicable 
local label recommendations if m ore stringent.
Table 7 Recommended Dose Modifications for Chemotherapy Hematological Toxicity
Pemetrexed Cisplatin/Carboplatin
Platelets ANC Dose level (DL) from Table 3
≥50,000/mcL  AND ≥500/mcL DL 0 DL 0
≥50,000/mcL  AND <500/mcL DL -1 DL -1
<50,000/mcL without 
bleeding ANDANY DL -1 DL -1
<50,000/mcL with Grade ≥2 
bleeding ANDANY DL -2 DL -2
ANY <1000/mcL + fever 
≥38.5°C (101°F)DL -1 DL -1
Table 8 Recommended Dose Modifications for Chemotherapy Non- Hematological 
Toxicity
Pemetrexed Cisplatin Carboplatin
Event CTC Grade Dose level (DL) from Table [ADDRESS_977377]: MK 3475 SCH 900475 71
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
6.8 Clinical Supplies Disclosure
This study is open- label; therefore, the participant, the study site personnel, the Sponsor, 
and/or designee are not blinded. Study intervention (name, strength, or potency) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
[ADDRESS_977378] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.3 (SoA) and 
Section 8.12.3.
Participants may discontinue study intervention at any time for any reason or be dropped 
from the s tudy intervention at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is vi olated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.9.
A participant must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
•The participant interrupts study intervention administration for more than 12consec utive 
weeks, unless approved with written documentation from Sponsor .
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirmed positive serum pregnancy test.
•If the i nvestigator performs a drug screen at his/her discretion and the participant has a 
positive urine drug screen at any time during the course of the study.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 72
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
•Confirmed radiographic disease progression outlined in Section 8. 2.1.2(exception if the 
Sponsor appro ves treatment continuation)
•Any progression or recurrence of any malignancy, or any occurrence of another 
malignancy that requires active treatment
•Noncompliance with study intervention or procedure requirements
•Recurrent Grade 2 pneumonitis
•Discontinuatio n of treatment may be considered for participants who have attained a 
confirmed complete response (CR) and have been treated for at least 8 cycles (at least 
24weeks), receiving at least [ADDRESS_977379] 80% of the planned doses of pemetrexed beyond the date 
when the initial CR was declared. 
•Completion of 35 treatments (approximately 2 years) with pembrolizumab
Note: The number of treatments is calculate d starting with the first dose.
7.[ADDRESS_977380] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a partic ipant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedly fail 
to return for scheduled visits and/or if the study site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_977381] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_2299] a nd reschedule the missed visit. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 73
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
•The investigator or designee must make every effort to regain contact [CONTACT_148197] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines.
8 STUDY ASSESSMENTS AND PROCEDURE S
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_148198]. Delegation of study site personnel responsibilities 
will be documented in the Investigator Trial File Binder (or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or b aseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, s uch evaluations/testing will be performed in accordance with those regulations.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 74
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
8.1 Administrative and General Procedures
Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant or each participant’s legally 
acceptable representative prior to participating in a clinical study or future biomedical 
research. If there are changes to the participant’s status during the study (eg, health or age of 
majority requirements), the investigator or medically qualified designee must ensure the 
appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by [CONTACT_2299]’s dated signature [INVESTIGATOR_4388] [CONTACT_2299]’s 
legally acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated 
signature [CONTACT_63564].
A copy of the signed and dated con sent form should be given to the participant before 
participation in the study.
The initial ICF, any subsequent revised written ICF, and any written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s) approval/favorable opi[INVESTIGATOR_19349]. The participant or his/her legally 
acceptable representative should be informed in a timely manner if new information becomes 
available that may be relevant to the participant’s willingness to continue participation in the 
study. The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the participant’s dated 
signature [INVESTIGATOR_4388] [CONTACT_2299]’s legally acceptable representative’s dated signature.
The participant or his/her legally acceptable representative will be asked to sign consent at 
the point of initial radiographic disease progression .
Specifics about a study and the study population will be add ed to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study. 
A copy of the informed consent will be given to the participant.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 75
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the s tudy.
Participant Identification Ca rd
All participants will be given a participant identification card identifying them as participants 
in a research study. The card will contain study site contact [CONTACT_3031] (including direct 
telephone numbers) to be use d in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation/randomiza tion, site personnel will add the treatment /randomization number to the 
participant identification card.
The participant identification card also contains contact [CONTACT_19430] a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
Medical History
A medical history will be obtained by [CONTACT_941] i nvestigator or qualified designee. The medical 
history will collect all active conditions and any condition diagnosed within the p rior 
10years that the i nvestigator considers to be clinically significant. Details regarding the 
disease for which the participant has enrolled in this study will be recorded separately and 
not listed as medical history.
Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
Theinvestigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] 28 days before starting the study. Treatment for the disease for which the participant 
has enrolled in this study will be recorded separately and not listed as a prior medication.
[IP_ADDRESS] Concomitant Medications
The i nvestigator or qualified designee will record medication, if any, taken by [CONTACT_717017] -up visit.
Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify the participant for all procedures that occur prior to intervention allocation . Each 
participant will be assigned only [ADDRESS_977382]: MK 3475 SCH 900475 76
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Assignment of Treatment/Randomization Numb er
All eligible partici pants wil l be allocated, by [CONTACT_210641], and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. The 
assigned screening number will become the participants’ treatment/randomization number. 
Once a treatment/randomization number is assigned to a participant, it can never be re -
assigned to another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
Study Intervention Administrati on
Administration of IV study medication (pembrolizumab and chemotherapy) will be 
witnessed by [CONTACT_941] i nvestigator and/or study staff.
Study treatment should begin on the day of treatment allocation or as close as possi ble to the 
date on which the participant is allocated/assigned.
[IP_ADDRESS] Timing of Dose Administration
Study interventions will generally be administered in the following order:  pembrolizumab, 
premedications, pemetrexed, and then carboplatin or cisplatin.  Details of administering the 
individual components are discussed below.
[IP_ADDRESS].1 Timing of Dose Administration of Pembrolizumab
Study treatment with pembrolizumab should be administered on Day 1 of each 21-day cycle 
after all procedures/assessments have been completed as detailed in the SoA (Section 1.3). 
All study treatments will be administered on an outpatient basis. Study treat ment of 
pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each 
21-day cycle due to administrative reasons except for C ycle 1 Day1, where the window is 
+3days from randomization.
Pembrolizumab will be administered as a dose of 200 mg using a 30- minute IV infusion. 
Sites should make every effort to target infusion timing to be as close to 30 minutes as 
possible. However, given the variability of infusion pumps from site to site, a window 
of -5minutes and +10 minutes is p ermitted (ie, infusion time is 30 minutes -5 min/+10 min).
The Pharmacy Manual contains specific instructions for pembrolizumab reconstitution, 
preparation of the infusion fluid, and administration.
[IP_ADDRESS].2 Timing of Dose Administration of Pemetrexed
Pemetrexed 500 mg/m2will be administered as an IV infusion over [ADDRESS_977383]: MK 3475 SCH 900475 77
PROTOCOL/AMENDMENT NO.: [ADDRESS_977384] 
of care chemotherapi[INVESTIGATOR_014].
[IP_ADDRESS].3 Timing of Dose of Carboplatin or Cisplatin
[IP_ADDRESS].3.1 Carboplatin
Carboplatin AUC 5 will be administered as an IV infusion over 30 to 60 minutes on Day1 of 
every 21-day cycle following pemetrexed infusions , for a maximum of 4 administrations.
[IP_ADDRESS].3.2 Cisplat in
Cisplatin 75 mg/m2will be administered as an IV infusion over a recommended time of 
60minutes. However, cisplatin may be administered over 30 to 150 minutes to accommodate 
local SOC. Treatment will be administered after pemetrexed on Day 1 of the 21-d ay cycle, 
for a maximum of 4 administrations.
Discontinuation and Withdrawal
Participants who discontinue study intervention prior to completion of the treatment period
should be encouraged to continue to be followed for all remaining study visits as outlined in 
the SoA (Section 1.3) and Section 8.12.3 .
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study visit should be performed (at the time of withdrawal). Any AEs
that are present at the time of withdrawal should be followed in accordance with the safety 
requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may 
withdraw consent at any time by [CONTACT_59554] [INVESTIGATOR_63472]. If 
medical records for the main study are still available, the investigator will contact [CONTACT_63527] . 
Subse quently, the participant's consent for future biomedical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility of the investigator to inform the participant of completion of withdrawal. Any 
06FWC3
CCI
0833R8
PRODUCT: MK 3475 SCH 900475 78
PROTOCOL/AMENDMENT NO.: [ADDRESS_977385] is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_180631]) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed. 
Participant Blinding/Unblindi ng
This is an open -label stu dy; there is no blinding for this study.
Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documen tation at the 
study site.
8.2 Efficacy/Immunogenicity Assessmen ts
Tumor Imaging and Assessment of Disease
All imaging will be completed and read locally per clinical SOC . 
Tumor imaging is strongly preferred to be acquired by [CONTACT_4654]. For the abdomen and pelvis, 
contrast -enhanced MRI may be used when CT with iodinated contrast is contraindicated, or 
when mandated by [CONTACT_53246]. MRI is the strongly preferred modality for imagi ng the 
brain. The same imaging technique regarding modality, ideally the same scanner, and the use 
of contrast should be used in a participant throughout the study to optimize the 
reproducibility of the assessment of existing and new tumor burden and improve the 
accuracy of the assessment of response or progression based on imaging. Note: for the 
purposes of assessing tumor imaging, the term “investigator” refers to the local investigator 
at the site and/or the radiological reviewer at the site or at an off site facility.
Participant eligibility will be determined using local assessment ( investigator assessment) 
based on RECIST 1.1.
Brain imaging is only required for participants with existing or suspected CNS metastases 
and/or carcinomatous meningitis. MRI is preferred; however, CT imaging with contrast will 
be acceptable, if MRI is medically contraindicated .Bone scans are also required for 
participants with a history of bone metastases and/or for those participants with new bone 
pain. 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 79
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS] Initial Tumor Imaging
Initial tumor imaging at screening must be performed within [ADDRESS_977386] is an acceptable alternative.
[IP_ADDRESS] Tumor Imaging During the Study
The first on -study imaging assessment should be performed at 6weeks ( 42days ±7 days) 
from the date of randomization.  The second on- study imaging assessment should be 
performed at 12 weeks ( 84 days ±7 days) from the date of randomization.  Subsequent tumor 
imaging should be performed every 9 weeks (63 days ±7 days) through W eek [ADDRESS_977387] imaging performed every 12 weeks (84 days ±7 days).  Imaging timing should follow 
calendar days and should not be adjusted for delays in cycle starts.  Imaging should continue 
to be performed until disease pro gression is identified by [CONTACT_093] (unless the site PI 
[INVESTIGATOR_716991]), the start of new anticancer treatment, 
withdrawal of consent, or death or notification by [CONTACT_1034], whichever occurs first.  
Objective resp onse should be confirmed by a repeat imaging assessment. Tumor imaging to 
confirm PR or CR should be performed at least [ADDRESS_977388] indication of a 
response is observed. Participants will then return to regular scheduled imaging, starting with 
the next scheduled imaging time point. Participants who receive additional imaging for 
confirmation do not need to undergo the next scheduled tumor imaging (ie, 9 or 12 weeks 
later) if it is less than 4 weeks later; tumor imaging may resume at the subseque nt scheduled 
imaging time point. 
Per iRECIST (Section [IP_ADDRESS]), disease progression in participants treated with 
pembrolizumab should be confirmed by [CONTACT_779] [ADDRESS_977389] met the conditions 
detailed in Section [IP_ADDRESS].  Participants who obtain a confirmation scan do not need to 
undergo the next scheduled tumor imaging if it is less than 4 weeks later; tumor imaging may 
resume at the subsequent scheduled imaging time point if clinically stable. Participants who 
have confirmed disease progression, as assessed by [CONTACT_779], will discontinue study treatment.  
Exceptions are detailed in Section [IP_ADDRESS].
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 80
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS] End-of-Treatment and Follow -up Tumor Imaging
For participants who discontinue study intervention, tumor imaging should be performed at 
the time of treatment discontinuation (±4 week window). If previous imaging was obtained 
within [ADDRESS_977390] .
For participants who discont inue study intervention without documented disease progression, 
every effort should be made to continue m onitoring disease status by [CONTACT_717018] (every 9weeks in Year 1 or 12weeks 
after Year 1) until the start of a new anticancer treatment, disease progression, pregnancy, 
death, withdrawal of consent , or the end of the study, whichever occurs first .
[IP_ADDRESS] RECIST 1.[ADDRESS_977391] 1.1 will be used as the primary measure for assessment of tumor response, date of 
disease progression, and as a basis for all protocol guidelines related to disease status (eg, 
discontinuation of study intervention). Although RECIST 1.1 references a maximum of 5 
target lesions in total and 2 per organ, th is protocol allows a maximum of 10 target lesions in 
total and 5 per organ, if clinically relevant to enable a broa der sampling of tumor burden.
[IP_ADDRESS] iRECIST Assessment of Disease
iRECIST is based on RECIST 1.1, but adapted to account for the unique tumor response seen 
with immunotherapeutic drugs. iRECIST will be used by [CONTACT_717019], and make treatment decisions. When clinically stable, participants 
should not be discontinued until progression is confirmed by [CONTACT_093], working with 
local radiology, according to the rules outlined in Appendix [ADDRESS_977392] few months after the start of 
immunotherapy, and then experience subsequent disease response. This data will be captured 
in the clinical database .
Clinical stability is defined as the following:
•Absence of symptoms and signs indicating clinically significant progression of disease
•No decline in ECOG performance status
•No requirements for intensified management, including increased analgesia, radiation, or 
other palliative ca re
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 81
PROTOCOL/AMENDMENT NO.: [ADDRESS_977393], as assessed by [CONTACT_093], and the 
participant continues to be clinically stable, study intervention may continue and follow the 
regular imaging schedule. If PD is confirmed, participants will be discontinued from study 
intervention.
If a participant has confirmed radiographic progression (iCPD) as define d in  Appendix 8 , 
study intervention should be discontinued; however, if the participant is achieving a 
clinically meaningful benefit, an exception to continue study intervention may be considered 
following consultation with the Sponsor. In this case, if study intervention is continued, 
tumor imaging should continue to be performed following the intervals as outlined in 
Section 1.3(SoA).
A description of the adaptations and iRECIST process is provided in Appendix 8, with 
additional details in the iRECIST p ublication [Seymour, L., et al 2017] . A summary of 
imagi ng and treatment requirements after first radiologic evidence of progression is provided 
in Table [ADDRESS_977394]: MK 3475 SCH 900475 82
PROTOCOL/AMENDMENT NO.: [ADDRESS_977395] 1.1 .Repeat imaging at 
4 to 8 weeks to 
confirm PD .May continue study 
intervention at the 
investigator’s 
discretion while 
awaiting 
confirmatory tumor 
imaging by [CONTACT_91079] .Repeat imaging at 4 
to 8 weeks to 
confirm PD per 
investigator’s 
discretion only .Discontinue 
treatment .
Repeat tumor 
imaging confirm s PD 
(iCPD) by [CONTACT_19442] .No additional 
imaging required .Discontinue 
treatment 
(exception is 
possible upon 
consultation with 
Sponsor).No additional 
imaging requiredNot applicable .
Repeat tumor 
imaging shows iUPD 
by [CONTACT_91082] .Repeat imaging at 
4 to 8 weeks to 
confirm PD. May 
occur at next 
regularly 
scheduled 
imaging visit .Continue study 
intervention at the 
investigator’s 
discretion.Repeat imaging at 4 
to 8 weeks to 
confirm PD per 
investigator’s 
discretion only.Discontinue 
treatment .
Repeat tumor 
imaging shows iSD, 
iPR, or iCR by 
[CONTACT_91082].Continue 
regularly 
scheduled 
imaging 
assessments.Continue study 
intervention at the 
investigator’s 
discretion.Continue regularly 
scheduled imaging 
assessments.May restart s tudy 
intervention if 
condition has 
improved and/or 
clinically stable per 
investigator’s 
discretion. Next 
tumor imaging 
should occur 
according to the 
regular i maging 
schedule.
iCPD iRECIST confirmed progressive disease; iCR iRECIST complete response; iRECIST modified Response Evaluation 
Criteria in Solid Tumors 1.1 for immune based therapeutics; iSD iRECIST stable disease; iUPD iRECIST unconfirmed 
progressive d isease; PD progressive disease; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 1.1; 
VOP verification of progression .
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the study 
(from prestudy to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_113802], can be found in the Procedures 
Manu al.
Planned time points for all safety assessments are provided in the SoA.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 83
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) as per institutional standard. Height ( at 
screening only) and weight will also be measured and recorded.
A brief directed physical examination will be conducted by [CONTACT_113803] (consistent with local requirements) per institutional standard.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
[IP_ADDRESS] Full Physical Examination
The investigator or qualified designee will perform a complete physical exam during the 
Screening period. Clinically significant abnormal findings should be recorded as medical 
history. The time points for full physical exams are described in Section 1.3 (SoA) . After the 
first dose of study intervention, new clinically significant abnormal findings should be 
recorded as AEs.
[IP_ADDRESS] Directed Physical Examination
For cycles that do not require a full physical exam as defined in Section 1.3 (SoA) , the 
investigator or qualified designee will perform a directed physical exam as clinically 
indicated prior to the administration of the study intervention. New clinically significant 
abnormal findings should be recorded as AEs.
Vital Signs
Vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_977396] and will include 
temperature, systolic and diastolic blood pressure, pulse ,and r espi[INVESTIGATOR_697] .
Electrocardiograms
Single 12- lead ECG will be obtained and reviewed by [CONTACT_88696] (consistent with local requirements) as outlined in the SoA using an ECG machine 
that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 84
PROTOCOL/AMENDMENT NO.: [ADDRESS_977397] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laborat ory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_78259]'s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_977398] be 
conducted in accordance with the Procedures M anual and the SoA .
•If laboratory values from nonprotocol specified laboratory assessments performed at the 
institution’ s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory t ests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_977399] dose of study intervention , every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
Details regarding specific laboratory procedures/assessments to be performed in this study 
are provided below. The total amount of blood/tissue to be drawn/collected over the cour se 
of the study (from prestudy to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_557445]. Refer to the S oA(Section 1.3) for the timing of labora tory assessments.
[IP_ADDRESS] Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)
Laboratory tests for hematology, chemistry, and urinalysis are specified in Appendix 2 .
[IP_ADDRESS] Pregnancy Test
All women who are being considered for participation in the study, and who are not 
surgically sterilized or postmenopausal, must be tested for pregnancy within [ADDRESS_977400] be excluded /discontinued from the study in the event of a positive 
test result. Repeated pregnancy test (such as clinic visit testing) may be conducted if required 
by [CONTACT_1295].
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 85
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Eastern Cooperative Oncology Group (ECOG) Performance Scale
The i nvestigator or qualified designee will assess ECOG status (see Appendix 10) at 
screening, prior to the administration of each dose of study intervention ,and during the 
follow -up period as specified in the SoA (Section 1.3).
8.4 Adverse Events (AEs), Serious Adverse Events (SA Es),and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event rep orts can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before intervention allocation/randomization must be reported by [CONTACT_717020] -in or other run -in treatment, if the event cause the 
participant to be excluded from the study, or is the result of a protocol -specified intervention, 
including but not limited to washout or dis continuation of usual therapy, diet, or a procedure.
All AEs from the time of intervention allocation/randomization through [ADDRESS_977401] be reported by [CONTACT_093].
All AEs meeting serious criteria, from the t ime of intervention allocation/randomization 
through [ADDRESS_977402] be reported by [CONTACT_941] i nvestigator.
All pregnancies and exposure during breastfeeding, from the time of intervention 
allocation/randomization through [ADDRESS_977403]: MK 3475 SCH 900475 86
PROTOCOL/AMENDMENT NO.: [ADDRESS_977404] be reported immediately to the Sponsor if the event is 
considered drug -related.
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a partic ipant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 10.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 87
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Table 10 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified 
Follow -up 
PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Information 
to Sponsor:
Nonserious Adverse 
Event (NSAE) Report if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data 
entry 
guidelines
Serious Adverse 
Event (SAE) 
including Cancer and 
OverdoseReport if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
(Follow ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes 
exclusionReport all Previously reported –
Follow to 
completion/termination; 
report outcomeWithin [ADDRESS_977405] (require 
regulatory reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
- potential drug -
induced liver 
injury ( DILI)
- require 
regulatory 
reportingNot required Within [ADDRESS_977406] (d o not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within [ADDRESS_977407]: MK 3475 SCH 900475 88
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events 
including pregnancy and exposure during breastfeeding, events of clinical interest (ECI s), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow- up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonse rious AEs that occur in 
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 3.
Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_717021] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory author ity and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply wth country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authori ties, IRB/IECs, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
An invest igator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or thei r designee), including the pregnancy of a male participant ’ s female 
partner, that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spont aneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 89
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Efficacy endpoint s, as described in Section 9.4.1, will not be reported to MSD .  
Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study.
MSD will monitor efficacy endpoint events and safety data to ensure the safety of the 
participants in the study.  Any suspected endpoint which upon review is not progre ssion of 
the cancer under study will be forwarded to MSD as an SAE within [ADDRESS_977408] (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor. 
Events of clinical interest for this study include: 
1)An overdose of Sponsor's product, as defined in Section 8.5, that is not associated 
with clinical symptoms or abnormal laboratory results.
2)An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value that 
is less than 2X the upper li mit of normal, as determined by [CONTACT_13149] -specified 
laboratory testing or unscheduled laboratory testing.* 
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may 
require an additional evaluation for an underlying etiology. The study site guidance 
for assessment and follow up of these criteria can be found in the Investigator Study 
File Binder (or equivalent).
8.5 Treatment of Overdose
For this study, an overdose of pembrolizumab will be defined as any dose of 1000 mg or 
greater ( ≥5 times the indicated dose).
No specific information is available on the treatment of overdose of pembrolizumab. In the 
event of overdose, the participant should be observed closely for signs of toxicity. 
Appropriate supportive treatment should be provided if clinically indicated.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 90
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
8.6 Pharmacokinetics
Pharmacokinetic paramete rs will not be evaluated in this study.
8.7 Pharmacodynamics
Pharmacodynamic markers will be evalu ated to gain a better understanding of response and 
resistance biology. Blood samples for a variety of exploratory biomarkers and planned 
genetic analysis will be collected at baseline, prior to and/or following treatment per the SoA 
(Section 1.3), at res ponse if it occurs, and at end of treatment/progression.  Detailed 
endpoints are described below in the biomarker section (Section 8.10).
8.8 Future Biomedical Research Sample Collection
The following specimens are to be obtained as part of future biomedical r esearch :
Leftover DNA for future research
Leftover main study plasma from metabolomics analysis stored for future research
Leftover main study serum from cytokine analysis stored for future research
Leftover main study RNA
Leftover main study tumor stored for future research
Leftover main study stool stored for future research
8.9 Planned Genetic Analysis Sample Collection
Sample collection, storage ,and shipment instructions for planned g enetic a nalysis samples 
will be provided in the Procedure s Manual.  
Samples should be collected for planned analysis of associations between genetic variants in 
germline/tumor DNA and drug response. If a documented law or regulation prohibits (or 
local IRB/Indepe ndent Ethics Committee [IEC] does not approve) sample collection for these 
purposes, then such samples should not be collected at the corresponding sites. Leftover 
DNA extracted from planned genetic analysis samples will be stored for future biomedical 
research only if participant signs the Future Biomedical Research consent.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 91
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
8.10 Biomarkers
Collection of samples for biomarker analysis supports primary endpoint , secondary 
endpoints , and explora tory endpoints in this study, as shown below . The following samples 
for biomarker research are required and will be collected from all participants in this study as 
specified in the SoA:
Whole b lood for the following ana lyses:
•cfDNA (primary endpoint and secondary endpoint )
•Cytokine analysis (exploratory endpoint )
•Genetic analysis (exploratory endpoint )
•RNA a nalysis (exploratory endpoint )
•Metabolomics analysis (exploratory endpoint )
Archival or newly obtained Stage IV tumor tissue for the following analyses:
•PD-L1 m olecular s tatus (exploratory endpoint)  
•WES for TMB ( exploratory endpoint)
•Other, eg: RNA, genetic ,or other exploratory biomarkers 
•Stool for microbiome analysis (exploratory endpoint)
Sample collection, storage, and shipment instructions for the exploratory biomarker 
specimens will be provided in the [COMPANY_006] Procedures Manual for this study.
Tissue Biomarkers
[IP_ADDRESS] PD-L1 IHC
Although not required for determining eligibility, pre -treatment PD -L1 status of tumor tissue 
will be recorded for each participant.  If PD- L1 results are not available from a participant’s 
diagnostic biopsy, PD -L1 IHC must be performed.  Analysis may be p erformed locally using 
PharmDx kit (Agilent, FDA approved for NSCLC), which uses the 22C3 antibody .  
Otherwise, adequate tumor tissue must be sent to the central tissue lab, Cova nce, for this 
analysis. Sample requirements, collection, storage, and shipment instructions are provided in 
the Procedure sManual.
[IP_ADDRESS] Exploratory Biomarkers
To be eligible to participate in the study, participants must provide sufficient evaluable Stage 
IV, archival solid tumor tissue sample or newly obtained core or excisional biopsy of a tumor 
lesion (that was not previously irradiated) for biomarker analysis (Fine Needle Aspi[INVESTIGATOR_1516] 
[FNA] samples will not be accepted). Formalin -fixed, paraffin embedded (FFPE) tissue 
blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. The 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 92
PROTOCOL/AMENDMENT NO.: [ADDRESS_977409] be provided to the 
central lab prior to Randomization.   
The planned Exploratory Biomarker tissue analyses will include the following:
WES for TMB (exploratory endpoint)
Other, eg: RNA, genetic, or other exploratory biomarkers 
Tissue sample requirements, collection, storage ,and shipment instructions are provided in 
the [COMPANY_006] Procedure sManual for this study.
Blood -based Biomarkers
Whole blood will be collected for primary and s econdary endpoints , and explorat ory 
biomarker analyses .  These collections are shown in the S oA and include: whole blood for 
cfDNA analysis, serum for cytokine analysis, blood for genetic analysis, blood for RNA 
analysis, and plasma for metabolomics analysis.
The [COMPANY_006] Procedures Manual details the requirements for sample collection, processing, 
storage and shipment for each of the blood -based biomarkers.
The Screening cfDNA collection is required for analyzing the primary endpoint of this study.  
For this most critical sample, please ensure that the [COMPANY_006] Procedures Manual is followed 
exactly for the collection, processing, storage, and shipment of this sample.  All cfDNA 
shipments must be shipped the same day of collection, via overnight expedited shippi[INVESTIGATOR_716992].
Stool -based Biomarkers
Stool samples will be collected for m icrobiome analysis per the S oA.  Of note, t wo (2) 
separate stool collections are required within [ADDRESS_977410] dose of therapy on C1D1. 
A single stool collection is required within 5 days prior to each of the designated on -
treatment study visits.  Site s should provide the participant with adequate stool collection kits 
and instructions for at -home collection of stool prior to the designate dstudy visit. 
Stool sample collection, storage ,and shipment instructions are provided in the [COMPANY_006] 
Procedure s Manual.
8.11 Heal th Economics Medical Resource Utilization and Health Economics
Not applicable.
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3 (SoA). Specific procedure -related details are 
provided in Section 8.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 93
PROTOCOL/AMENDMENT NO.: [ADDRESS_977411] dose of 
study intervention except for the following:
•Laboratory tests are to be performed within [ADDRESS_977412] dose of study intervention.
•Evaluation of ECOG i s to be performed within [ADDRESS_977413] dose of study 
intervention.
•For women of reproductive potential, a urine or serum pregnancy test will be performed 
within [ADDRESS_977414] will be required (performed by 
[CONTACT_79428]).
•Archival tumor sample collection is not required to be obtained within [ADDRESS_977415] dose of study intervention. Newly obtained tumor tissue may be obtai ned within 
90 days of treatment initiation.
Participants may be rescreened after initially failing to meet the inclusion/exclusion criteria. 
Results from assessments during the initial screening period are acceptable in lieu of a repeat 
screening test if p erformed within the specified time frame and the corresponding 
inclusion/exclusion criteri onis met. Participants who are rescreened will retain their original 
screening number.
Treatment Period
Visit requirements are outlined in the SoA (Section 1.3). Spe cific procedure -related details 
are provided in Section 8.
Discontinued Participants Continuing to be Monitored in the Study
[IP_ADDRESS] Safety Follow -up Visit
The mandatory Safety Follow -up Visit should be conducted approximately [ADDRESS_977416].
All AEs that occur prior to the Safety Follow -Up Visit should be recorded. Participants with 
an AE of Grade >[ADDRESS_977417]: MK 3475 SCH 900475 94
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
days of the end of treatment or before initiation of a new anticancer treatment should also be 
followed and recorded.
[IP_ADDRESS] Follow -up Visits
Participant s who discontinue study treatment for a reason other than disease progression will 
move into the Follow -Up Phase and should be assessed approximately every [ADDRESS_977418] survival status to be assessed at addit ional 
time points during the course of the study (not to exceed approximately 12 weeks) .  Every 
effort should be made to collect information regarding disease status until the start of new 
anticancer therapy, disease progression, death, or end of study as detailed in Section 1.3 
(SoA) .  Information regarding post -study anticancer treatment will be collected if new 
treatment is initiated .
[IP_ADDRESS] Survival Follow -up
Participants who experience confirmed disease progression or start a new anticancer therapy 
will move into the Survival Follow- up Phase and should be contact[CONTACT_717022] [ADDRESS_977419].
Survival Status
To ensure current and com plete survival data is available at the time of database locks, 
updated survival status may be requested during the course of the study by [CONTACT_1034]. For 
example, updated survival status may be requested prior to but not limited to an external Data 
Monit oring Committee (eDMC) review, interim and/or final analysis. Upon Sponsor 
notification, all participants who do not/will not have a scheduled study visit or study contact 
[CONTACT_193438] ( excluding 
participants that have a previously recorded death event in the collection tool).
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study.  Changes 
to analyses made after the protocol has been finalized, but prior to final database lock, will be 
documented in a supplemental SAP (sSAP) and referenced in the Clinical Study Report for 
the study. Details around the analysis approach for biomarker endpoints related to the 
explorator y objectives are deemed out of scope for this SAP, but may be the subject of 
sSAPs.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 95
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.[ADDRESS_977420]- Line Non-
Small Cell Lung Cancer ( KEYNOTE -782)
Treatment Assignment Participant s will receive : 
(1)Pembrolizumab 200 mg Q3W in combination with 
carboplatin AUC 5mg/mL/min Q3W IV and 
pemetrexed 500 mg/m2Q3W IV for 4 cycles followed 
by [CONTACT_717023] 200 mg Q3W IV with 
pemetrexed maintenance 500 mg/m2Q3W IV.
OR
(2)Pembrolizumab 200 mg Q3W in combination with 
cisplatin 75mg/m2Q3W IV and pemetrexed 500 mg/m2
Q3W IV for 4 cycles followed by [CONTACT_717024] 200 mg Q3W IV with pemetrexed 
maintenance 500 mg/m2Q3W IV.
Analysis Populations All Subjects as Treated (ASaT)
Primary Efficacy Endpoint 1)Objective response (OR) :  Complete response (CR) or partial 
response (PR)
Primary Biomarker 
Endpoint1)Baseline tumor mutation burden (TMB) in circulating cell -free 
DNA (cfDNA) (blood)
Key Secondary Endpoints 1)PFS is defined as the time from the start of treatment to the first 
documented progressive disease (PD) or death due to any cause, 
whichever occurs first.   
2)OS is defined as the time from the start of treatment to death due 
to any cause.
Statistical Methods for Key 
Efficacy/Immunogenicity/ 
Pharmacokinetic AnalysesFor the primary objective, the posterior probability that the coefficient 
for baseline TMB in cfDNA is greater than zero in a logistic regression 
model of objective response (yes/no) will be used to estimate the level of 
association of baseline TMB in cfDNA and objective response in 
NSCLC participants treated with pembrolizumab + platinum -doublet
chemotherapy .
Statistical Methods for Key 
Safety AnalysesDescriptive summary statistics will be provided.
Interim Analyses A preliminary analysis of the primary objective : an evaluation of the 
level of association of TMB in cfDNA and objective response will occur 
approximately [ADDRESS_977421] patient enrolled (LPE).
Final analysis will occur after all participants have received [ADDRESS_977422]: MK 3475 SCH 900475 96
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Early Clinical Development Statistics Department of the Sponsor .
This trial is being conducted as an unblinded ,open -label study; ie, participants, investigators, 
and Sponsor personnel will be aware of participant treatment assignments after each 
participant is enrolled and treatment is assigned.
Biomarker assays used to assess the primary, secondary ,and tertiary/exploratory objectives 
in this stud y will be performed by [CONTACT_717025] ’ clinical outcome data.
9.3 Hypotheses/Estimation
Objectives of the study are stated in Section 3.
9.4 Analysis Endpoints
Efficacy Endpoints
Primary Efficacy Endpoint
1)Objective Response :  defined as confirmed CR or PR between the start of the study 
treatment and disease progression/recurrence (or death due to any cause, whichever 
occurs first) as assessed by [CONTACT_26309] 1.1. Atreated participant
will be designated as a ‘responder’ if he/she achieves a confirmed CR or confirmed 
PR and designed as a ‘non -responder’ otherwise. Participants with missing response
data are considered non -responders.
Secondary Efficacy Endpoints
2)Progression -Free Survival (PFS):  defined as the time from start of treatment to the 
first documented PD (per investigator assessed RECIST 1.1) or death due to any 
cause, whichever occurs first. 
3)Overall Survival (OS):  defined as the time from start of treatment to death due to a ny 
cause. 
Biomarker Endpoints
Primary and Secondary Biomarker Endpoints
The primary and secondary biomarker endpoint is baseline TMB in cfDNA from blood 
detailed in Section [IP_ADDRESS].[ADDRESS_977423]: MK 3475 SCH 900475 97
PROTOCOL/AMENDMENT NO.: [ADDRESS_977424] of supplementary SAPs .
Safety Endpoints
Refer to Section [IP_ADDRESS] for the description of safety measures.
9.5 Analysis Populations
The All Subjects as Treated (ASaT) population will be used for the analysis of the prima ry, 
secondary ,and exploratory objectives. The ASaT population consists of all subjects who 
received at least 1dose of study treatment. Subjects will be included in the treatment group 
corresponding to the study treatment they actually received for the analysis of primary, 
secondary ,and exploratory objectives using the ASaT population.
9.6 Statistical Methods
Statistical Methods for Biomarker/Efficacy Analyses
This section describes the statistical methods that address the pri mary and secondary 
objectives. Me thods related to exploratory objectives will be described in supplemental 
SAPs.
Those generating the biomarker data willremain blinded to a participant’s clinical status as a 
responder or non-responder per RECIST 1.1 (investigator -assessed) inorder to preserve an 
objective evaluation of the study objectives. Dem ographic and baseline characteristics of 
responders and non -responders will be tabulated.
Primary Objective
Logistic regression modeling of responders (CR or PR) and non -responders will be used to 
estimate the level of association of baseline TMB in cfDNA andobjective response in 
NSCLC participants treated with pembrolizumab + investigator choice platinum -doubl et 
chemotherapy (pemetrexed plus investigator choice of either cisplatin or carboplatin) . The 
logistic regression model will include a term for independent variable:  continuous log 10
transformed TMB in cfDNA and dependent variable:  objective response (ye s/no) . The 
posterior probability that the coefficient for cfDNA TMB is greater than zero in the logistic 
regression model will be reported. In addition, logistic regression models adjusting for 
ECOG performance status, smoking status ,and other relevant clinical variables will be 
evaluated to assess the importance of these prognostic factors and support the robustness of 
TMB in cfDNA findings. Sensitivity analyses using raw scale and square root 
transformations of TMB in cfDNA will be explored to handle any zero- inflation in the TMB 
in cfDNA data. The association of baseline TMB in cfDNA with objective response will also 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 98
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
be evaluated using the area under the ROC curve (AUROC). The distribution of baseline 
TMB in cfDNA will be graphicall y displa yed and summarized (mean, median, and standard 
deviation) by [CONTACT_717026] (CR or PR) v ersus non- responders.
Secondary Objectives
Cox regression modeling will be used to estimate the level of association of baseline TMB in 
cfDNA andsurvival ( PFS or O S).The Cox regression model swill include a term for the 
independent variable:  continuous log 10transformed TMB in cfDNA and dependent 
variables:  PFS or OS . Participants without documented progression or death at the time of 
analysis will be censored at the date of the last adequate assessment. The posterior 
probability that the coefficients for cfDNA TMB are less than zero in the Cox regression 
models will be reported . In addition, Cox regression models adjusting for ECOG 
performance status, smoking sta tus,and other relevant clinical variables will be evaluated to 
assess the importance of these prognostic factors and support the robustness of TMB in 
cfDNA findings. Sensitivity analyses using raw scale and square root transformations of 
TMB in cfDNA will be explored to handle any zero -inflation in the TMB in cfDNA data.
Exploratory Objectives
Details around the analysis approach for biomarker endpoints related to the exploratory 
objectives are deemed out of scope for this SAP, but will be the subject of s upplemental 
SAPs.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 99
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Table 11 summari zes the estimation strategy for the primary and secondary objectives 
detailed above.
Table 11 Analysis S trategy for Primary and S econdary O bjectives
Endpoint/Vari able
(Description, Time Point)Primary vs. 
Supportive 
Approach1Statistical Method2Analysis 
PopulationMissing Data 
Approach
Primary Objective
Objective Response (OR) P Posterior probability of 
TMB coefficient in 
logistic regression3ASaT Study 
participants with 
missing data are 
considered non -
responders .
Objective Response (OR) S AUROC ASaT Study 
participants with 
missing data are 
considered non -
responders .
Secondary Objective
Progression -free survival (PFS) P Posterior probability of 
TMB coefficient in 
Cox regression4ASaT Censored at the 
date of last 
adequate 
assessment
Overall survival (OS) P Posterior probability of 
TMB coefficient in 
Cox regression4ASaT Censored at the 
date of last 
follow -up
  1ASaT All Subjects as Treated; cfDNA circulating free deoxyribonucleic acid; P Primary approach ; 
PFS progression free survival; S Supportive approach ; TMB tumor mutation burden.
  2Statistical models are described in further detail below:
  3Logistic regression model ,including term for independent variable baseline cfDNA TMB and dependent variable 
OR (yes/no CR or PR) . The posterior probability of the TMB coefficient in logistic regression models adjusting for 
ECOG performance status, smoking status ,and other relevant clinical variables will be evaluated as a supportive 
approach.
  4Cox regression model ,including term for independent variable baseline cfDNA TMB and dependent variables PFS 
or OS . The posterior probability of the TMB coefficient in Cox regression models adjusting for ECOG performance 
status, smoking status ,and other relevant clinical variables will be evaluated as a supportive approach.
Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by [CONTACT_14339] ,
including AEs, SAEs, laboratory tests, vital signs, etc.
Descriptive summary statistics will be provided for safety endpoints. For continuous 
measures such as changes from baseline in laboratory tests and vital signs, summary statistics 
for baseline, on -treatment, and change from baseline values will be provided in table format.
Additional safety endpoints may also be summarized as deemed clinically appropriate.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 100
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
9.7 Interim Analyses
A preliminary analysis of the primary objective :  an evaluation of the level of association of 
TMB in cfDNA and objective response will occur approximately [ADDRESS_977425] patient 
enrolled (LPE).
9.[ADDRESS_977426] received 35 
administrations of pembrolizumab or discontinued study intervention.
9.9 Multiplicity
No multiplicity adjustment will be applied to the primary or secondary analyses. 
9.10 Sample Size and Power Calculations
This study will enroll approximately 100participants. This provides 80% power to detect a 
coefficient for cfDNA TMB greater than zero in a logistic regression model for objective 
response with type I error rate of 5% (one -sided) and with mean fold increase in median 
cfDNA TMB for responders v ersus non- responders of 1.78 ,assuming a 50% ORR . 50% 
ORR is consistent with data from KEY NOTE- 021G and K EYNOTE- 189, where in the same 
treatment setting response rates of 56.7% and 47.6%, respectively, were observed.
Historically, an approximate 60% increase in the median WES TMB for responders 
compared to non- responders to pembrolizumab monotherapy has been observed in bladder 
and head and neck squamous cell carcinoma (HNSCC) ,indications which are most similar to 
NSCL C.Recent NSCLC pembrolizumab monotherapy- treated WES TMB data are in 
alignment with historical data. A linear relationship between WES TMB data and TMB in 
cfDNA data is assumed. 
While historical data provide evidence of a 60% increase in the median WES TMB for 
responders compared to non -responders, it is important to note the fold increase is in 
reference to response to treatment with pembrolizumab monotherapy. The fold increase i n 
the median TMB for responders v ersus non- responders treated with pembrolizumab plus 
chemotherapy may lessen from that expected forpembrolizumab monotherapy if 
chemotherapy generates objective responses independent of the level of the biomarker, TMB. 
Table 12 shows the mean fold increase of median TMB in cfDNA for responders compared 
to non- responders from 10,000 simulated datasets with 80% and 90% power to detect a
coefficient for TMB in cfDNA greater than zero with type I error rate of 5% (one -sided) for 
varying objective response rates (ORR) . The simulations used to generate Table 12 make the 
following assumptions:  TMB in cfDNA is normally distributed on the log 10scale with equal 
variance between responders and non -responders, the mean TMB in cfDNA of responders is 
a positive shift from the mean TMB in cfDNA of non -responder s,and the variance of TMB 
in cfDNA is0.[ADDRESS_977427]: MK 3475 SCH 900475 101
PROTOCOL/AMENDMENT NO.: [ADDRESS_977428] a statistically significant association at one -sided
α 0.05 with underlying fold- change (responders/non -responders) less than 1.78 (closer to the 
historical 1.60), an estimation approach to the primary and secondary study objectives was 
taken.
Table 12 Mean Fold Increase in the Total Tumor M utation Burden (TMB) in C irculating 
Free DNA (cfDNA) for Responders Compared to Non-responders W ith 80% and 90% P ower 
to Detect a Coefficient for cfDNA TMB G reater T han Zero for Varying Objective Response 
Rates (ORR)
NResponse 
Rate (%)Mean Fold Increase in TMB in cfDNA
Responders vs. Non -Responders
with 80% Power1Mean Fold Increase in TMB in cfDNA
Responders vs. Non -Responders
with 90% Power1
[ZIP_CODE] 1.78 1.98
45 1.78 1.97
50 1.78 1.95
55 1.78 1.95
1Based on 10,000 generated datasets; power evaluated f rom logistic regression models at α=0.05 (one-sided)
9.11 Subgroup Analyses
Not applicable .
9.12 Compliance (Medication Adherence)
Drug accountability data for study treatment will be collected during the study.  Any 
deviation from protocol -directed administration will be reported.
9.13 Extent of Exposure
The extent of exposure to study treatment will be evaluated by [CONTACT_148216] (eg, N, 
mean, median, standard deviation, etc. ) for dura tion of treatment in cycles.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 102
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
Code of Conduct for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD )
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Hel sinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator initiated trials , which are not under the 
full control of M SD.
II.Scientific Is sues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to addre ss the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP noncompliance is suspected, the issues 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 103
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results o f its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_716993] , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contri bution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona lReview Board [IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time and labor intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 104
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the inve stigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be
consistent with local guidelines and practices .
V. Investigator Commitment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific stan dards.
Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_717027] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to pr ovide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that ar e transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 105
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the invest igator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confid entiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_717028], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/I EC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_717029] r ecords of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
Committees Structure
[IP_ADDRESS] Steering Committee
This study will be conducted in consultation with a Steering Committee. The Steering 
Committee is compo sed of Sponsor personnel and representatives of GRAIL, Inc.
The Steering Committee will provide guidance on the operational aspects of the study.
Specif ic details regarding responsibilities and governance of the Steering Committee will be 
described in a separate charter.
Publication Policy
The results of this study may be published or presented at scientific meetings. The Sponsor 
will comply with the requirements for publication of study results. In accordance with 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 106
PROTOCOL/AMENDMENT NO.: [ADDRESS_977429] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as S ponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to iden tify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_111968].
By [CONTACT_12570], the investig ator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to those 
registries.
Comp liance with Law, Audit, and Debarmen t
By [CONTACT_12570], the investigator agrees to conduct the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally 
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 107
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist i n responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on c linical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or de signee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management proc edures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_111969] e Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 108
PROTOCOL/AMENDMENT NO.: [ADDRESS_977430] 
be retained by [CONTACT_1732] 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or party without written notific ation to the Sponsor.
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and stud y records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.
Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a p articular study site, the Sponsor will 
promptly notify that study site’s IRB/IEC.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 109
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 13will be perfo rmed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Sections 5.1and 5.2 .
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 13 Protocol -required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic-
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic- Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose 
(nonfasting)Calcium Alkaline 
phosphatase
Routine 
Urinalysis •Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
Other Screening 
Tests •Follicle -stimulating hormone (as needed in women of nonchildbearing potential only)
• β human chorionic gonadotropin (β hCG) pregnancy test (as needed for WOCBP)
within [ADDRESS_977431] dose
Thyroid panel: TSH, FT4, FT3/T3Serology
NOTES:
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 110
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (includi ng 
placebo, active comparator product, or run -in intervention) , manufactured by, licensed 
by, provided by, or distributed by [CONTACT_63553].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinica l chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacer bation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “acc idental or intentional overdose without adverse effect.”
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 111
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurren ce did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgery planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_977432] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/inca pacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 112
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
Additional Events Reported in the Same Manner as SAE
Additional events that require reporting in the same manner as SAE
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to th e Sponsor in the same time frame as SAEs to 
meet certain local requirements. Therefore, these events are considered serious by [CONTACT_19510].
•Is a new cancer (that is not a condition of the study)
•Is associated with an overdose
Record ing AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all r elevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 113
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity/t oxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
The investigator will make an assessment of intensity for each AE and SAE (and ot her 
reportable safety event) according to the NCI Common Terminology for Adverse Events 
(CTCAE), version 4. Any AE that changes CTCAE grade over the course of a given epi[INVESTIGATOR_716994] /worksheets.
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Grade 2: Moderate; minimal, local ,or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living (ADL).
Grade 3 :  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care 
ADL.
Grade 4: Life threatening consequences; urgent intervention indicated.
Grade 5: Death related to AE.
Assessment of c ausality
Did the Sponsor’s product cause the AE?
The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria b elow are 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 114
PROTOCOL/AMENDMENT NO.: [ADDRESS_977433] and the AE based upon the available information.
The following components are to be used to assess the relationship between the Sponsor’s 
product and the AE; the greater the correlation with the components and their respective 
elements (in number and/or intensity), the more likely the Sponsor’s product caused the AE:
Exposure:  Is there evidence that the participant was actually exposed to the Sponsor’s 
product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], diary, etc.), 
expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course:  Did the AE follow in a reas onable temporal sequence from administration of 
the Sponsor’s product? Is the time of onset of the AE compatible with a drug -induced effect 
(applies to studies with investigational medicinal product)?
Likely Cause:  Is the AE not reasonably explained by [CONTACT_121283], other drug(s)/vaccine(s), or other host or environmental factors.
Dechallenge:  Was the Sponsor’  product discontinued or dose/exposure/frequency reduced?
If yes, did the AE resolve or improve?
If yes, this is a p ositive dechallenge.
If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; 
(2) the AE resolved/improved despi[INVESTIGATOR_55530]’s product; (3) the study is 
a single -dose drug study; or (4) Sponsor’s product(s) is/are only used 1 time.)
Rechallenge:  Was the participant re -exposed to the Sponsor’s product in this study?
If yes, did the AE recur or worsen?
If yes, this is a positive rechallenge.
If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability, or (2) the study is a single -dose drug study; or (3) Sponsor’s product(s) is/are used 
only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT ,THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_19513], AND IF REQUIRED, THE 
IRB/IEC.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 115
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Consistency with study intervention profile:  Is the clinical/pathological presentation of the 
AE consistent with previous knowledge regarding the Sponsor’s product or drug class 
pharmacology or toxicology?
The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_78031] a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
Yes, there is a reasonable possibility of Sponsor’s product relationship:
There is evidence of exposure to the Sp onsor’s product. The temporal sequence of the AE 
onset relative to the administration of the Sponsor’s product is reasonable. The AE is more 
likely explained by [CONTACT_1034]’s product than by [CONTACT_5748].
No, there is not a reasonable possibility of Spons or's product relationship:
Participant did not receive the Sponsor’s product OR temporal sequence of the AE onset 
relative to administration of the Sponsor’s product is not reasonable OR the AE is more 
likely explained by [CONTACT_26372]’s p roduct. (Also entered for a participant 
with overdose without an associated AE.)
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
There may be situations i n which an SAE has occurred, and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that 
the investigator always make an assessment of causality for every event before the initial 
transmi ssion of the SAE data to the Sponsor.
The investigator may change his/her opi[INVESTIGATOR_9242] -up information 
and send an SAE follow- up report with the updated causality assessment.
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
For studies in which multiple agents are administered as part of a combination regimen, the 
investigator may attribute each AE causality to the combination regimen or to a single agent 
of the combination. I n general, causality attribution should be assigned to the combination 
regimen (ie, to all agents in the regimen). However, causality attribution may be assigned to a 
single agent if in the investigator’s opi[INVESTIGATOR_1649], there are sufficient data to support full attribution 
of the AE to the single agent.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 116
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in t he CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated dat a 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 117
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and s ign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent).
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 118
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.4 Appendix 4: Device Events, Adverse Device Ev ents, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 119
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined a s no menses for 12 months without an alternative 
medical cause .
•A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormone replacement thera py (HRT). However, in the absence of [ADDRESS_977434]: MK 3475 SCH 900475 120
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Contraception Requirements
Male Participants
Male participants with fem ale partners of childbearing potential are eligible to participate if 
they agree to 1 of the following during the protocol -defined time frame in Section 5.1:
•Be abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent.
•Use a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse with a WOCBP who is not currently pregnant.
-The following are not acceptable me thods of contraception:
•Periodic abstinence (calendar, symptothermal, postovulation methods), 
withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea
method (LAM).
•Male condom with cap, diaphragm, or sponge with spermicide.
•Male and f emale condom cannot be used together.
-Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_191202]. 
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to 
consistent and correct use of a highly effective method of contraception that has a low user 
dependency as described in Table [ADDRESS_977435]: MK 3475 SCH 900475 121
PROTOCOL/AMENDMENT NO.: [ADDRESS_977436] Low User Depe ndency 
Failure rate of <1% per year when used consistently and correctly.
●Progestogen only contraceptive implanta,b
●Intrauterine hormone- releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be u sed. 
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence n eeds to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants of 
clinical studies.
aIf locally required, in accordance with Cl inical Trial Facilitation Group guidelines, acceptable 
contraceptive implants are limited to those which inhibit ovulation.
bIf hormonal contraception efficacy is potentially decreased due to interaction with study intervention, 
condoms must be used in addition to the hormonal contracept ion during the intervention period and for at 
least 120 days (corresponding to time needed to eliminate study intervention plus 30 days for study 
interventions with genotoxic potential ) after the last dose of study intervention.
Pregnancy Testing
WOCBP should only be included after a negative highly sensitive urine or serum pregnancy 
test and in accordance with local requirements. This test should be repeated a maximum of 
72hours before the first dose.
Following initiation of treatment, additional pregn ancy testing will be performed at every 
study visit during the treatment period and at [ADDRESS_977437]: MK 3475 SCH 900475 122
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
Definitions
1. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
2. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
3. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
4. DNA: Deoxyribonucleic acid.
5. RNA: Ribonucleic acid.
Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8.8 will be 
used in various experiments to understand:
◦The biology of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
◦Other pathways drugs/vaccines may interact with
◦The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 123
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Summary of Procedures for Future Biomedical Research.
1.Participants for Enrollment
All parti cipants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
2.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at n ext possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
3.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified
will be destroyed.
4.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. In 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be con ducted. Knowing 
participant characteristics like gender, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 124
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
At the clinical study site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices. Analyses utilizing the future biomedical r esearch specimens may be performed 
by [CONTACT_1034], or an additional third party (eg, a university investigator) designated by 
[CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in this substudy. Future biomedical r esearch 
specimens remaining with the third party after specific analysis is performed will be 
reported to the Sponsor.
Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at any time by [CONTACT_59554] [INVESTIGATOR_63472]. If medical 
records for the main study are still av ailable, the investigator will contact [CONTACT_90095] . 
Subsequently, the participant's specimens will be flagged in the biorepository and 
restricted to main study use only. If specimens wer e collected from study participants 
specifically for future biomedical r esearch, these specimens will be removed from the 
biorepository and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. I t is the responsibility of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request be ing received by [CONTACT_259711]. No new analyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_111974]) or the specimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_977438]: MK 3475 SCH 900475 125
PROTOCOL/AMENDMENT NO.: [ADDRESS_977439] supervision in a limited access facility which 
operates to assure the integrity of the specimens. Specimens will be destroyed according 
to Sponsor policies and procedures and this destruction will be documented in the
biorepository database.
Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
Reporting of Future Biomedical Research Data to Participants
No information obtained f rom exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_716995]. Participants will not be 
identified by [CONTACT_88726].
Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 126
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Questions
Any questions related to the future biomedical research should be e mailed directly to 
References
3)National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid [ZIP_CODE]
4)International Conference on Harmonization [Internet] : E15: Definitions for 
Genomic Biomarkers, Pharmacogenomics, Pharmaco genetics, Genomic Data and 
Sample Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -
pharmacogenetics -genomic -data-and-sample -cod.html 
5)Industry Phar macogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide 
for IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
6)Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
06FWC3
CCI
0833R8
PRODUCT: MK 3475 SCH 900475 127
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.7 Appendix 7: Country -specific Requirements
Not applicable.     
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 128
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.8 Appendix 8: Description of the iRECIST Process for Assessment of Disease 
Progression
Assessment at Screening and Prior to RECIST 1.[ADDRESS_977440] for participant manag ement (see 
Table 9 ). This decision by [CONTACT_19517]’s overall 
clinical condition.
Clinical stability is defined as the following:
•Absence of symptoms and signs indicating clinically significant progression of disease
•No decline in ECOG performance status
•No requirements for intensified management, including increased analgesia, radiation, or 
other palliative care
Any participant de emed clinically unstable should be d iscontinued from study intervention at    
site-assessed first radiologic evidence of PD, and is not required to have repeat tumor 
imaging for confirmation of PD by [CONTACT_19393].
If the investigator decides to continue treatment, the participant may continue to receive 
study intervention and the tumor assessment should be repeated [ADDRESS_977441] 1.1, 
including:
•Increase in the sum of diameters of target lesion(s) identified at baseline to ≥20% and 
≥5mm from nadir
Note: The iRECIST publication uses the terminology “sum of measurements,” but “sum 
of diameters” will be used i n this protocol, consistent with the original RECIST 1.1 
terminology.
•Unequivocal progression of nontarget lesion(s) identified at baseline
•Development of new lesion(s)
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 129
PROTOCOL/AMENDMENT NO.: [ADDRESS_977442] defines new response categories, including iUPD (unconfirmed progressive 
diseas e) and iCPD (confirmed progressive disease). For purposes of iRECIST assessment, 
the first visit showing progression according to RECIST 1.1 will be assigned a visit (overall) 
response of iUPD, regardless of which factors caused the progression.
At this vi sit, target and nontarget lesions identified at baseline by [CONTACT_393] 1.[ADDRESS_977443] 1.1. From measurable new 
lesions, up to 5 lesions total (up to 2 per organ), may be selected as New Lesions Target. 
The sum of diameters of these lesions will be calculated, and kept distinct from the sum of 
diameters for target lesions at baseline. All other new lesions will be followed qualitatively 
as New Lesions Non- target.
Assessment at the Confirmatory Imaging
On the confirmatory imaging, the participant will be classified as progression confirmed 
(with an overall response of iCPD), or as showing persistent unconfirmed progression (with 
an overall response of iUPD), or as showing disease stability or response (iSD/iPR/iCR).
Confirmation of Progression
Progression is considered confirmed, and the overall response will be iCPD, if ANY of the 
following occurs:
•Any of the factors that were the basis for the iUPD at the previous visit show worsening
-For target lesions, worsening is a further increase in the sum of diameters of ≥5 mm, 
compared to any prior iUPD time point
-For nontarget lesions, worsening is any sig nificant growth in lesions overall, 
compared to a prior iUPD time point; this does not have to meet the “unequivocal” 
standard of RECIST 1.1
-For new lesions, worsening is any of these:
◦An increase in the new lesion sum of diameters by ≥5 mm from a prior iUPD time 
point
◦Visible growth of new nontarget lesions
◦The appearance of additional new lesions
•Any new factor appears that would have triggered PD by [CONTACT_393] 1.[ADDRESS_977444]: MK 3475 SCH 900475 130
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Persistent iUPD
Progression is considered not confirmed, and the overall response remai ns iUPD, if:
•None of the progression -confirming factors identified above occurs AND
•The target lesion sum of diameters (initial target lesions) remains above the initial PD 
threshold (by [CONTACT_393] 1.1)
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging on 
which iUPD is seen. This may correspond to the next visit in the original visit schedule. The 
assessment of the subsequent confirmation imaging proceeds in an identical manner, with 
possible outcomes of iCPD, iUPD, and iSD/i PR/iCR.
Resolution of iUPD
Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, if:
•None of the progression -confirming factors identified above occurs, AND
•The target lesion sum of diameters (initial target lesions) is not above the initial PD 
threshold.
The response is classified as iSD or iPR (depending on the sum of diameters of the target 
lesions), or iCR if all lesions resolve.
In this case, the initial iUPD is considered to be pseudo -progression, and the level of 
suspi[INVESTIGATOR_19367] “reset.” This means that the next visit that shows radiographic 
progression, whenever it occurs, is again classified as iUPD by [CONTACT_19393], and the 
confirmation process is repeated before a response of iCPD can be assigned.
Management Following the Confirmatory Imaging
If repeat imaging does not confirm PD per iRECIST, as assessed by [CONTACT_093], and the 
participant continues to be clinically stable, study treatment may continue and follow the 
regular imaging schedule. If PD is confirmed, participants will be discontinued from study 
treatment.
NOTE: If a participant has confirmed radiographic progression (iCPD) as defined above, but 
the participant is achieving a clinically meaningful benefit, an exception to continue study 
interve ntion may be considered following consultation with the Sponsor. In this case, if study 
intervention is continued, tumor imaging should continue to be performed following the 
intervals as outlined in Section 1.[ADDRESS_977445]: MK 3475 SCH 900475 131
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
Detection of Progression at Visits After Pseudo -progression Resolves
After resolution of pseudo- progression (ie, achievement of iSD/iPR/iCR), iUPD is indicated 
by [CONTACT_19518]:
•Target lesions
-Sum of diameters reaches the PD threshold ( ≥20% and ≥5mm increase from nadir) 
either for the first time, or after resolution of previous pseudo- progression. The nadir 
is always the smallest sum of diameters seen during the entire study, either before or 
after an instance of pseudo -progression.
•Nontarget lesions
-If non target lesions have never shown unequivocal progression, their doing so for the 
first time results in iUPD.
-If nontarget lesions have shown previous unequivocal progression, and this 
progression has not resolved, iUPD results from any significant further growth of 
non-target lesions, taken as a whole.
•New lesions
-New lesions appear for the first time
-Additional new lesions appear
-Previously identified new target lesions show an increase of ≥5 mm in the new lesion 
sum of diameters, from the nadir value of that sum
-Previously identified non -target lesions show any significant growth
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging abov e) is repeated. 
Progression must be confirmed before iCPD can occur.
The decision process is identical to the iUPD confirmation process for the initial PD, with 
one exception: If new lesions occurred at a prior instance of iUPD, and at the confirmatory 
imaging the burden of new lesions has increased from its smallest value (for new target 
lesions, the sum of diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve 
to iSD or iPR. It will remain iUPD until either a decrease in the new lesion bur den allows 
resolution to iSD or iPR, or until a confirmatory factor causes iCPD.
Additional details about iRECIST are provided in the iRECIST publication [Seymour, L., et 
al 2017] .
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 132
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.9 Appendix 9: Abbreviations
Abbreviation Expanded Term
ADL activities of daily living
AE adverse event
ALK anaplastic lymphoma kinase
aPTT activated partial thromboplastin time
ASaT All Subjects as Treated
AUC area under the time -concentration curve
BICR blinded independent central review
B-RAF B isoform of rapi[INVESTIGATOR_11907]
C1D1 Cycle [ADDRESS_977446] ratio
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
Ig immunoglobulin
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 133
PROTOCOL/AMENDMENT NO.: [ADDRESS_977447] immune -related Response Evaluation Criteria in Solid Tumors
IUD intrauterine device
IV intravenous
IVRS interactive voice response system
KRAS a proto -oncogene derived from Kirsten RAt Sarcoma virus
mAb monoclonal antibody
MRI magnetic resonance imaging
MSD [COMPANY_006] Sharp & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc.
MSI microsatellite instability
NR not reached
NSCLC non-small cell lung cancer
OR objective response
ORR objective response rate
OS overall survival
PD progressive disease
PD-[ADDRESS_977448] upper limit of normal
WES whole exome sequencing
WOCBP woman/women of childbearing potential 
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 134
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
10.10 Appendix 10:Eastern Cooperative Oncology Group (ECOG) Performance Scale
Developed by [CONTACT_64850], Robert L. Comis, MD, Group 
Chair.* 
GRADE ECOG Performance Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambu latory and able to carry 
out work of a light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities; up and about more than 50% of waking hours
3 Capable of only limite d self -care; confined to bed or chair more than 50% 
of waking hours
4 Completely disabled; cannot carry on any self -care; totally confined to bed 
or chair
5 Dead
*Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology 
Group. Am J Clin Oncol. 1982;5:[ADDRESS_977449]: MK 3475 SCH 900475 135
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
11 REFERENCES
[Alexander, J. L., et al 2017] Alexander JL, Wilson ID, Teare J, Marchesi 
JR, Nicholson JK, Kinross JM. Gut microbiota 
modulation of chemotherapy efficacy and 
toxicity. Nat Rev Gas troenterol Hepatol. 2017 
Jun;14:356- 65.[04Y5MB]
[Aravanis, A. A., et al 2018] Aravanis AA, Oxnard GR, Maddala T, Hubbell 
E, Venn O, Jamshidi A, et al. Development of 
plasma cell- free DNA (cfDNA) assays for early 
cancer detection: first insights from the 
Circulating Cell- free Genome Atlas study 
(CCGA) [abstract]. Presented at: 2018 
American Association for Cancer Research 
(AACR) Annual Meeting; 2018 Apr 14- 18; 
Chicago, IL. Abstract no. LB -343.[04YCX5]
[Belkaid, Y. 2017] Belkaid Y, Harrison OJ. Homeos tatic immunity 
and the microbiota. Immunity. 2017 Apr 
18;46:562- 76.[04Y5M7]
[Castle, J. C., et al 2012] Castle JC, Kreiter S, Diekmann J, Lower M, 
van de Roemer N, de Graaf J. et al. Exploiting 
the mutanome for tumor vaccination. Cancer 
Res. 2012 Mar 1;7 2(5):1081- 91.[04MLPX]
[Chanudet, E., et al 2007] Chanudet E, Adam P, Nicholson AG, 
Wotherspoon AC, Ranaldi R, Goteri G, et al. 
Chlamydiae and Mycoplasma infections in 
pulmonary MALT lymphoma. Br J Cancer. 
2007;97(7):949- 51.[04Y4GY]
[Chemnitz, J. M., et al 2004] Chemnitz JM, Parry RV, Nichols KE, June CH, 
Riley JL. SHP -1 and SHP -2 associate with 
immunoreceptor tyrosine -based switch motif of 
programmed death 1 upon primary human T 
cell stimulation, but only receptor ligation 
prevents T cell activation. J Immunol 
2004;173:945- 54.[00VMPN]
[Cummings, J. H., et al 1987] Cummings JH, Pomare EW, Branch WJ, 
Naylor CPE, Macfarlane GT. Short chain fatty 
acids in human large intestine, portal, hepatic 
and venous blood. Gut. 1987;28:1221- 7.[04Y5ZW]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 136
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Disis, M. L. 2010] Disis ML. Immune regulation of cancer. J Clin 
Oncol 2010;28(29):4531 -8.[058SQL]
[Dudley, M. E., et al 2005] Dudley ME, Wunderlich JR, Yang JC, Sherry 
RM, Topalian SL, Restifo NP, et al. Adoptive 
cell transfer therapy following non -
myeloablative but lymphodepleting 
chemotherapy for the treatment of patients with 
refractory metastatic melanoma. J Clin Oncol 
2005;23(10):2346 -57.[00VMPR]
[Francisco, L. M., et al 2010] Francisco LM, Sage PT, Sharpe AH. The PD -[ADDRESS_977450] in tolerance and au toimmunity. 
Immunol Rev 2010;236:219 -42.[058SQP]
[Gadgeel, S., et al 2016] Gadgeel S, Stevenson J, Langer C, Gandhi L, 
Borghaei H, Patnaik A, et al. Pembrolizumab 
plus chemotherapy as front -line therapy for 
advanced NSCLC: KEYNOTE- 021 cohorts A -
C. Poster session presented at: The American 
Society of Clinical Oncology; 2016 Jun 3- 7; 
Chicago, IL.[04HX6N]
[Gandhi, L., et al 2018] Gandhi L, Rodriguez -Abreu D, Gadgeel S, 
Esteban E, Felip E, De Angelis F, et al. 
Pembrolizumab plus chemotherapy in 
metastatic non- small -cell lung cancer. N Engl J 
Med. In press 2018.[04X2M4]
[Gopalakrishnan, V., et al 
2018]Gopalakrishnan V, Helmink BA, Spencer CN, 
Reuben A, Wargo JA. The influence of the gut 
microbiome on cancer, immunity, and cancer 
immunotherapy. Cancer Cell. 2018 Apr 
9;33:570 -80.[04Y63M]
[Greenwald, R. J., et al 2005] Greenwald RJ, Freeman GJ, Sharpe AH. The 
B7 family revisited. Annu Rev Immunol 
2005;23:515- 48.[00VMQL]
[Haase, S., et al 2018] Haase S, Haghikia A, Wilck N, Muller DN, 
Linker RA. Impacts of microbiome metabolites 
on immune regulation and autoimmunity. 
Immunology. In press 2018.[04Y643]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 137
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Hellmann, M. D., et al 2018] Hellmann MD, Ciuleanu TE, Pluzanski A, Lee 
JS, Otterson GA, Audigier -Valette C, et al. 
Nivolumab plu s ipi[INVESTIGATOR_716996] a high tumor mutational burden. N Engl J 
Med. 2018 May 31;378(22):2093 -104.[04YCWH]
[Hodi, F. S., et al 2014] Hodi FS, Ribas A, Daud A, Hamid O, Robert 
C, Kefford R, et al. Patterns of response in 
patients with advanced m elanoma treated with 
Pembrolizumab (MK -3475) and evaluation of 
immune -related response criteria (irRC). J 
Immunother Cancer. 2014;2(Suppl 3):P103.[0465RW]
[Hooper, S. J., et al 2007] Hooper SJ, Crean SJ, Fardy MJ, Lewis MAO, 
Spratt DA, Wade WG, et al. A molecular 
analysis of the bacteria present within oral 
squamous cell carcinoma. J Med Microbiol. 
2007;56:1651- 9.[04Y63B]
[Hubbard, A. L., et al 1998] Hubbard AL, Harrison DJ, Moyes C, McOrist 
S. Direct detection of eae -positive bacteria in 
human and vet erinary colorectal specimens by 
[CONTACT_954]. J Clin Microbiol. 1998 Aug;36(8):2326 -
30.[04Y645]
[Hunder, N. N., et al 2008] Hunder NN, Wallen H, Cao J, Hendricks DW, 
Reilly JZ, Rodmyre R, et al. Treatment of 
metastatic melanoma with autologous CD4+ T 
cells agains t NY -ESO -1. N Engl J Med 
2008;358(25):2698 -703.[00VMPX]
[Iida, N., et al 2013] Iida N, Dzutsev A, Stewart CA, Smith L, 
Bouladoux N, Weingarten RA, et al. 
Commensal bacteria control cancer response to 
therapy by [CONTACT_717030]. Scie nce. 2013 Nov 
22;342:967- 70.[04Y5Y9]
[Kim, C. H. 2018] Kim CH. Immune regulation by [CONTACT_717031]. Immunology. In press 2018.[04Y5Y4]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 138
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Langer, C. J., et al 2016] Langer CJ, Gadgeel SM, Borghaei H, 
Papadimitrakopoulou VA, Patnaik A, Powell 
SF, et al. Carboplatin and pemetrexed with or 
without pembrolizumab for advanced, non -
squamous non -small -cell lung cancer: a 
randomised, phase [ADDRESS_977451] 
9. [Epub ahead of print].[04JNLW]
[Le, D., et al 2015] Le D, Uram J, Wang H, Bartlett B, Kemberling 
H, Eyring A, et al. PD- 1 blockade in tumours 
with mismatch repair deficiency. Poster session 
presented at The American Society of Clinical 
Oncology, 2015 May 30; Chicago, IL.[04HGBM]
[Linnemann, C., et al 2015] Linnemann C, van Buuren MM, Bies L, 
Verdegaal EME, Schotte R, Calis JJA, et al. 
High- throughput epi[INVESTIGATOR_716997] -antigens by [CONTACT_398]4+ 
T cells in human melanoma. Nat Med. 2015 
Jan;21(1):81 -5. Erratum in: Nat Me d. [ADDRESS_977452] 
6;22(10):1192.[04Y5Y0]
[Lloyd, C. M. 2017] Lloyd CM, Marsland BJ. Lung homeostasis: 
influence of age, microbes, and the immune 
system. Immunity. 2017 Apr 18;46:549 -61.[04Y5XH]
[Lopes, G., et al 2018] Lopes G, Wu Y, Kudaba I, Kowalski D, Cho
BC, Castro G, et al. Pembrolizumab (pembro) 
versus platinum -based chemotherapy (chemo) 
as first -line therapy for advanced/metastatic 
NSCLC with a PD -L1 tumor proportion score 
(TPS) ≥ 1%: open -label, phase 3 KEYNOTE-
042 study [abstract]. Presented at: The 
American Society of Clinical Oncology 
(ASCO) Annual Meeting; 2018 Jun 1 -5; 
Chicago, IL. J Clin Oncol. 2018;36(suppl). 
Abstract no. LBA4.[04Y5G9]
[Luo, A., et al 2017] Luo A, Leach ST, Barres R, Hesson LB, 
Grimm MC, Simar D. The microbiota and 
epi[INVESTIGATOR_532758] T helper 17/regulatory 
T cells: in search of a balanced immune 
system. Front Immunol. 2017 Apr 10;8:417.[04Y5XG]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 139
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Matson, V., et al 2018] Matson V, Fessler J, Bao R, Chongsuwat T, 
Zha Y, Alegre ML, et al. The commensal 
microbiome is associated with anti -PD-1 
efficacy in metastatic melanoma patients. 
Science. 2018 Jan 5;359:104- 8.[04Y435]
[Matsushita, H., et al 2012] Matsushita H, Vesely MD, Koboldt DC, 
Rickert CG, Uppaluri R, Magrini VJ, et al. 
Cancer exome analysis reveals a T -cell-
dependent mechanism of cancer 
immunoediting. Nature. 2012 Feb;482:400 -4.[04Y40R]
[Meng, C., et al 2018] Meng C, Bai C, Brown TD, Hood LE, Tian Q. 
Human gut microbiota and gastrointestinal 
cancer. Genomics Proteomics Bioinformatics. 
2018;16:33- 49.[04Y44 7]
[National Cancer Institute 
2016]National Cancer Institute. SEER Stat Fact 
Sheets: Lung and bronchus cancer [Internet]. 
Bethesda, MD: National Cancer Institute; 2016. 
Available from: 
http://seer.cancer.gov/statfacts/.[04FJVR]
[Okazaki, T., et al 2001] Okazaki T, Maeda A, Nishimura H, Kurosaki 
T, Honjo T. PD -1 immunoreceptor inhibits B 
cell receptor -mediated signaling by [CONTACT_306190] 2- domain- containing tyrosine 
phosphatase 2 to phosphotyrosine. Proc Natl 
Acad Sci U S A 2001;98(24):[ZIP_CODE] -71.[00VMQ6]
[Parry, R. V., et al 2005] Parry RV, Chemnitz JM, Frauwirth KA, 
Lanfranco AR, Braunstein I, Kobayashi SV, et 
al. CTLA -[ADDRESS_977453] mechanisms. Mol Cell 
Biol 2005;25(21):9543- 53.[00VMQ7]
[Rea, D., et al 2018] Rea D, Coppola G, Palma G, Barbieri A, 
Luciano A, Del Prete P, et al. Microbiota 
effects on cancer: from risks to therapi[INVESTIGATOR_014]. 
Oncotarget. 2018 Apr 3;9(25):[ZIP_CODE]- 27.[04Y5HM]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 140
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Reck, M., et al 2016] Reck M, Rodriguez -Abreu D, Robinson AG, 
HuiR, Csoszi T, Fulop A, et al. 
Pembrolizumab versus Chemotherapy for PD -
L1-Positive Non- Small- Cell Lung Cancer. N 
Engl J Med. [ADDRESS_977454] 8. [Epub ahead of print].[04JNM3]
[Riley, J. L. 2009] Riley JL. PD -1 signaling in primary T cells. 
Immunol Rev 2009;229: 114-25.[00VMQ9]
[Rizvi, N. A., et al 2015] Rizvi NA, Hellmann MD, Snyder A, Kvistborg 
P, Makarov V, Havel JJ, et al. Mutational 
landscape determines sensitivity to PD -1 
blockade in non- small cell lung cancer. 
Science. 2015 Apr 3;348(6230):124 -8.[04Y4PT]
[Robbins, P. F., et al 2013] Robbins PF, Lu YC, El -Gamil M, Li YF, Gross 
C, Gartner J, et al. Mining exomic sequencing 
data to identify mutated antigens recognized by 
[CONTACT_622342] -reactive T cells 
[manuscript]. Nat Med. 2013 Jun;19(6):747 -52.[04Y4LG]
[Rooks, M. G. 2016] Rooks MG, Garrett WS. Gut microbiota, 
metabolites and host immunity. Nat Rev 
Immunol. 2016 Jun;16:341 -52.[04Y4VK]
[Routy, B., et al 2018] Routy B, Le Chatelier E, Derosa L, Duong 
CPM, Alou MT, Daillere R, et al. Gut 
microbiome influences efficacy of PD -1-based 
immunotherapy against epi[INVESTIGATOR_220]. 
Science. 2018 Jan 5;359:91- 7.[04Y66F]
[Schumacher, T. N. 2015] Schumacher TN, Schreiber RD. Neoantigens in 
cancer immunotherapy. Science. 2015 Apr 
3;348(6230):69- 74.[04Y4MS]
[Seymour, L., et al 2017] Seymour L, Bogaerts J, Perrone A, Ford R, 
Schwartz LH, Mandrekar S, et al. iRECIST: 
guidelines for response criteria for use in trials 
testing immunotherapeutics. Lancet Oncol. 
2017 Mar;18(3):e143 -52.[04P9RV]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 141
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Sheppard, K-A, et al 2004] Sheppard K- A, Fitz LJ, Lee JM, Benander C, 
George JA, Wooters J, et al. PD -1 inhibits T -
cell receptor induced phosphorylation of the 
ZAP70/CD3zeta signalosome and downstream 
signaling to PKCtheta. FEBS Lett. 
2004;574:37- 41.[00VMQC]
[Shukla, S. D., et al 2017] Shukla SD, Budden KF, Neal R, Hansbro PM. 
Microbiome effects on immunity, health and 
disease in the lung. Clin Transl Immunology. 
2017 Mar 10;6:e133.[04Y67J]
[Silva -Valenzuela, C. A., et al 
2016]Silva -Valenzuela CA, Desai PT, Molina -
Quiroz RC, Pezoa D, Zhang Y, Porwollik S, et 
al. Solid tumors provide niche -specific 
conditions that lead to preferential growth of 
Salmonella. Oncotarget. 2016;7(23):[ZIP_CODE] -80.[04Y6CV]
[Snyder, A., et al 2014] Snyder A, Makarov V, Merghoub T, Yuan J, 
Zaretsky JM, Desrichard A, et al. Genetic basis 
for clinical response to CTLA -4 blockade in 
melanoma. N Engl J Med. 2014 Dec 
4;371(23):2189- 99.[04Y6CW]
[Stockinger, B., et al 2014] Stockinger B, Di Meglio P, Gialitakis M, 
Duarte JH. The aryl hydrocar bon receptor: 
multitasking in the immune system. Annu Rev 
Immunol. 2014;32:403 -32.[04Y5PH]
[Sulpher, J. A., et al 2013] Sulpher JA, Owen SP, Hon H, Tobros K, 
Shepherd FA, Sabri E, et al. Factors 
influencing a specific pathologic diagnosis of 
non-small -cell lung carcinoma. Clin Lung 
Cancer. 2013 May;14(3):238 -44.[040565]
[Tran, E. 2014] Tran E, Rosenberg SA. T -cell therapy against 
cancer mutations. Oncotarget. 2014 Jul 
19;5(13):4579- 80.[04Y5PG]
[Van Allen, E. M., et al 2015] Van Allen EM, Miao D, Schilling B, Shukla 
SA, Blank C, Zimmer L, et al. Genomic 
correlates of response to CTLA -[ADDRESS_977455] 
9;350(6257):207 -11. Erratum in: Science. 2015 
Nov 13;350(6262):aad8366.[04Y8N4]
06FWC3
0833R8
PRODUCT: MK 3475 SCH 900475 142
PROTOCOL/AMENDMENT NO.: 782 02 
MK 3475 [ZIP_CODE] FINAL PROTOCOL 20AUG 2021
[Vetizou, M., et al 2015] Vetizou M, Pi[INVESTIGATOR_313818], Daillere R, Lepage P, 
Waldschmitt N, Flament C, et al. Anticancer 
immunotherapy by [CONTACT_485] -4 blockade relies on 
the gut microbiota. Science. 2015 Nov 
27;350(6264):1079 -84.[04Y8N3]
[Wolchok, J. D., et al 2009] Wolchok JD, Hoos A, O'Day S, Weber JS, 
Hamid O, LebbéC, et al. Guidelines for the 
evaluation of immune therapy activity in solid 
tumors: immune -related response criteria. Clin 
Cancer Res 2009;15(23):7412 -20.[00VMNZ]
[World Health Organization 
2012]Globocan 2012: Lung Cancer Estima ted 
Incidence, Mortality and Prevalence 
Worldwide in 2012 [Internet]. Lyon (FR): 
World Health Organization, International 
Agency for Research on Cancer (IARC). c2014 
[updated [ADDRESS_977456] 3]. Available from: 
http://globocan.iarc.fr/Pages/fact_sheets_cancer
.aspx[0402K4]
[Wroblewski, L. E., et al 
2010]Wroblewski LE, Peek RM Jr, Wilson KT. 
Helicobacter pylori and gastric cancer: factors 
that modulate disease risk. Clin Microbiol Rev. 
[ADDRESS_977457];23(4):713 -39.[04Y8N5]
[Yuan, J. 2016] Yuan J. Circulating protein and antibody 
biomarker for personalized cancer 
immunotherapy. J Immunother Cancer. 
2016;4:46.[04Y8DN]
[Zhang, X., et al 2004] Zhang X, Schwartz J -CD, Guo X, Bhatia S, 
Cao E, Chen L, et al. Structural and functional 
analysis of the costimulatory receptor 
programmed death- 1. Immunity 2004;20:337-
47.[00VMQJ]
[Zitvogel, L., et al 2018] Zitvogel L, Ma Y, Raoult D, Kroemer G, 
Gajewski TF. The microbiome in cancer 
immunotherapy: diagnostic tools and 
therapeutic strategies. Science. 2018 Mar 
23;359:1366- 70.[04Y8F0]
06FWC3
0833R8